{"code":1,"isDone":false,"toInsertArticleList":[{"createdTime":"2021-05-19 23:04:05","updatedTime":"2021-05-19 23:04:05","title":"NK免疫细胞疗法：为何沦为癌症患者的 “超级杀手”？","link":"http://weixin.sogou.com/weixin?type=2&query=%E7%9F%A5%E8%AF%86%E5%88%86%E5%AD%90+NK%E5%85%8D%E7%96%AB%E7%BB%86%E8%83%9E%E7%96%97%E6%B3%95%EF%BC%9A%E4%B8%BA%E4%BD%95%E6%B2%A6%E4%B8%BA%E7%99%8C%E7%97%87%E6%82%A3%E8%80%85%E7%9A%84%20%E2%80%9C%E8%B6%85%E7%BA%A7%E6%9D%80%E6%89%8B%E2%80%9D%EF%BC%9F","description":"<div><div><div id=\"media\" class=\"rich_media_thumb_wrp\">\n\n            <img class=\"rich_media_thumb\" src=\"http://content.sov5.cn/mmbiz_jpg/LHibUTtMHPRNtvz5A1gm8NxTXLPQMoXf0DLmDYriaoYbN5DVU0nFXL0E7njd47P0eARF0IQq5bUiadbtIkwOSIWSw?imageView2/1/w/600\">\n        </div>\n    \n\n    \n\n    <div class=\"rich_media_content\" id=\"js_content\">\n                    \n\n                    \n                    \n                    \n                    <section powered-by=\"xiumi.us\" data-mpa-powered-by=\"yiban.io\"><p style=\"line-height: 1.75em;padding: 0px 0.5em;margin-left: 8px;margin-right: 8px;\"><img data-ratio=\"0.6638889\" data-type=\"jpeg\" data-w=\"1080\" style=\"box-sizing: border-box; vertical-align: middle; width: 677px !important; visibility: visible !important; box-shadow: rgb(210, 210, 210) 0em 0em 0.5em 0px; font-size: 17px; max-width: 600px\" src=\"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_jpg/cyUibDfJJTsLu3ibSvvVmNBabkAnLK5ickhIiac5rIKPRyD5xv4Ee2I8fwVz2cm6azsocJLWcncDuj4xZicdXh6cQMA/640?wx_fmt=jpeg\"></p></section><section powered-by=\"xiumi.us\"><p style=\"margin-left: 16px;margin-right: 16px;line-height: normal;\"><br></p></section><section powered-by=\"xiumi.us\"><section data-role=\"outer\" label=\"Powered by 135editor.com\"><section data-tools=\"135编辑器\" data-id=\"104006\" data-width=\"95%\" style=\"margin-left: auto;margin-right: auto;width: 95%;flex: 0 0 95%;\"><section style=\"text-align: left;margin: 10px auto;\"><section style=\"display: flex;justify-content: flex-end;margin-right: 15px;margin-bottom: -20px;\"><section style=\"width: 35px;\"><img data-ratio=\"1.2745098039215685\" data-type=\"png\" data-w=\"51\" data-width=\"100%\" style=\"box-sizing:border-box; width: 100%; display: block; max-width: 600px\" src=\"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_png/LHibUTtMHPRNtvz5A1gm8NxTXLPQMoXf0q4fyb0U0Ys019Hg3UNyJAohZPHHgko2LdopWCbdKTASAUywxFrx2WA/640?wx_fmt=png\"></section></section><section style=\"background-image: linear-gradient(to right, rgb(255, 255, 255) 0%, rgb(255, 255, 255) 5%, rgb(240, 248, 253) 5%, rgb(240, 248, 253) 100%);background-position: initial;background-size: initial;background-repeat: initial;background-attachment: initial;background-origin: initial;background-clip: initial;padding-top: 35px;\"><section style=\"background-image: url(\" https: left bottom no-repeat initial><section powered-by=\"xiumi.us\" style=\"white-space: normal;\"><section><section powered-by=\"xiumi.us\"><section><section><section powered-by=\"xiumi.us\"><section><section style=\"line-height: 1.75em;margin-bottom: 10px;margin-left: 8px;margin-right: 8px;\"><span style=\"color: rgb(0, 122, 170);letter-spacing: 2px;\"><strong><span style=\"color: rgb(0, 122, 170);letter-spacing: 1px;font-size: 16px;\">划重点 <em>！！</em></span></strong></span></section><p style=\"margin: 15px 8px 10px;line-height: 1.75em;\"><strong><span style=\"letter-spacing: 1px;color: rgb(255, 255, 255);font-size: 15px;background-color: rgb(60, 132, 175);font-size: 15px;\"> 1 </span></strong><span style=\"font-size: 15px;color: rgb(78, 65, 65);letter-spacing: 1px;\"> 我们体内免疫细胞的攻击性非常强大，它们不仅能杀死癌细胞，也能杀死某些正常细胞，促进免疫系统释放大量的免疫因子，所以免疫细胞疗法所产生的副作用也正在于此。</span></p><section style=\"margin-right: 8px;margin-left: 8px;line-height: 1.75em;margin-bottom: 10px;\"><strong><span style=\"font-size: 15px;color: rgb(78, 65, 65);letter-spacing: 1px;background-color: rgb(60, 132, 175);\"> </span></strong><span style=\"color: rgb(255, 255, 255);\"><strong><span style=\"font-size: 15px;letter-spacing: 1px;background-color: rgb(60, 132, 175);\">2</span></strong></span><strong><span style=\"font-size: 15px;color: rgb(78, 65, 65);letter-spacing: 1px;background-color: rgb(60, 132, 175);\"> </span></strong><span style=\"font-size: 15px;color: rgb(78, 65, 65);letter-spacing: 1px;\"> NK免疫细胞疗法依然处于早期研发阶段，全球多数该类型药物处于I期临床试验阶段。</span></section><section style=\"margin-right: 8px;margin-left: 8px;line-height: 1.75em;margin-bottom: 10px;\"><strong><span style=\"font-size: 15px;letter-spacing: 1px;color: rgb(255, 255, 255);background-color: rgb(60, 132, 175);\"> 3 </span></strong><span style=\"font-size: 15px;color: rgb(78, 65, 65);letter-spacing: 1px;\"> 魏则西生前接受的免疫细胞疗法系“DC-CIK生物免疫疗法”，目前仍未有DC-CIK免疫细胞疗法类型药物获批上市，仅有早期临床科学试验在实施。</span></section></section></section></section></section></section></section></section><section powered-by=\"xiumi.us\" style=\"white-space: normal;\"><section><section powered-by=\"xiumi.us\"><section><section><section powered-by=\"xiumi.us\"><section><section style=\"margin-right: 8px;margin-left: 8px;line-height: 1.75em;margin-bottom: 10px;\"><strong><span style=\"font-size: 15px;letter-spacing: 1px;color: rgb(255, 255, 255);background-color: rgb(60, 132, 175);\"> 4 </span></strong><span style=\"font-size: 15px;color: rgb(78, 65, 65);letter-spacing: 1px;\"> 免疫细胞疗法费用高昂，主要在于该治疗方法有繁杂的环节和生产成本。</span></section></section></section></section></section></section></section></section><section powered-by=\"xiumi.us\" style=\"white-space: normal;\"><section><section powered-by=\"xiumi.us\"><section><section><section powered-by=\"xiumi.us\"><section><p style=\"margin-right: 8px;margin-left: 8px;line-height: 1.75em;\"><span style=\"color: rgb(255, 255, 255);\"><strong><span style=\"font-size: 15px;letter-spacing: 1px;background-color: rgb(60, 132, 175);\"> 5 </span></strong></span><span style=\"font-size: 15px;color: rgb(78, 65, 65);letter-spacing: 1px;\"> 癌症患者是否需要使用免疫细胞疗法，首先需要了解处于肿瘤病程的哪个阶段，是否已经接受了相关治疗。</span></p></section></section></section></section></section></section></section></section></section></section></section></section></section><section style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\"><section style=\"display: flex;justify-content: flex-start;align-items: flex-start;\"><section data-autoskip=\"1\"><p><br></p><section style=\"margin-left: 16px;margin-right: 16px;line-height: 2em;\"><strong><span style=\"font-size: 16px;letter-spacing: 1px;\">撰文 | 甘蔚</span></strong></section><p style=\"text-align: center;\"><br></p></section></section></section><section powered-by=\"xiumi.us\"><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;text-align: center;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"><span style=\"letter-spacing: 1px;text-align: center;background-color: rgb(255, 255, 255);font-size: 12px;font-family: -apple-system-font, BlinkMacSystemFont, \" helvetica neue sc sans gb yahei ui arial sans-serif rgb>●              </span><span style=\"text-align: center;background-color: rgb(255, 255, 255);font-size: 12px;font-family: -apple-system-font, BlinkMacSystemFont, \" helvetica neue sc sans gb yahei ui arial sans-serif rgb>　</span><span style=\"letter-spacing: 1px;text-align: center;background-color: rgb(255, 255, 255);font-size: 12px;font-family: -apple-system-font, BlinkMacSystemFont, \" helvetica neue sc sans gb yahei ui arial sans-serif rgb>●              </span><span style=\"text-align: center;background-color: rgb(255, 255, 255);font-size: 12px;font-family: -apple-system-font, BlinkMacSystemFont, \" helvetica neue sc sans gb yahei ui arial sans-serif rgb>　</span><span style=\"letter-spacing: 1px;text-align: center;background-color: rgb(255, 255, 255);font-size: 12px;font-family: -apple-system-font, BlinkMacSystemFont, \" helvetica neue sc sans gb yahei ui arial sans-serif rgb>●</span></span></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><br></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">“北医三院医生张煜指责上海新华医院医生陆巍诱骗治疗事件” 仍在发酵，因为不认可国家卫健委的调查结果，张煜持续在社交平台发声。</span></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><br></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">5年前，陕西的肿瘤患者魏则西接受<strong>细胞免疫治疗</strong></span><span style=\"font-size: 16px;letter-spacing: 1px;color: rgb(136, 136, 136);\">（DC-DIK）</span><span style=\"font-size: 16px;letter-spacing: 1px;\">，救治无果去世；5年后，张煜再次把矛头对准了免疫细胞疗法，这一次的主角换成了<strong>NK免疫细胞疗法</strong>。</span></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><br></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">5年的时间，虽然不同种类的 “免疫细胞疗法” 在科学和临床研究上均有重大突破，但其临床试验现状、癌症治疗的规范和监管机制等仍然面临重重挑战。</span></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><br></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">对于患者而言，如何从繁杂的信息源里，获取关于免疫细胞疗法的科学认知，辨别伪科学下的种种骗局，对患者科学抗癌十分重要。就此，本文汇总了个民众最关心的问题并逐一解答。</span></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><br></section></section><section powered-by=\"xiumi.us\"><p style=\"line-height: 1.75em;padding: 0px 0.5em;margin-left: 8px;margin-right: 8px;\"><img data-croporisrc=\"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_png/cyUibDfJJTsLu3ibSvvVmNBabkAnLK5ickhzKaHZHEQ1UpJToAgTry7w0pcxjEhKuQzhPr4czGTfzUozf2ibMjCePQ/640?wx_fmt=png\" data-cropx1=\"0\" data-cropx2=\"621\" data-cropy1=\"0\" data-cropy2=\"419\" data-ratio=\"0.6747181964573269\" data-type=\"jpeg\" data-w=\"621\" style=\"box-sizing: border-box; vertical-align: middle; box-shadow: rgb(210, 210, 210) 0em 0em 0.5em 0px; font-size: 17px; width: 578px; visibility: visible !important; height: 390px; max-width: 600px\" src=\"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_jpg/LHibUTtMHPRNtvz5A1gm8NxTXLPQMoXf0GicvfCbjohObvb5F0Z08lQZUz7RsDGuIruXKpqRibIVLPLPmib5K9XgJA/640?wx_fmt=jpeg\"></p></section><section powered-by=\"xiumi.us\"><p style=\"margin-left: 16px;margin-right: 16px;line-height: 3em;\"><br></p></section><section powered-by=\"xiumi.us\"><section><section powered-by=\"xiumi.us\"><section data-role=\"outer\" label=\"Powered by 135editor.com\"><section data-tools=\"135编辑器\" data-id=\"102525\" data-width=\"95%\" style=\"margin-left: auto;margin-right: auto;width: 95%;flex: 0 0 95%;\"><section style=\"margin: 10px auto;text-align: center;\"><section style=\"display: flex;justify-content: center;align-items: center;\" hm_fix=\"232:390\"><section style=\"background-image: linear-gradient(to right, rgba(253, 123, 119, 0) 0%, rgb(141, 179, 226) 100%);height: 1px;margin-left: 6px;flex: 1 1 0%;overflow: hidden;\"><br></section><section style=\"margin-right: 10px;margin-left: 10px;\"><section style=\"width: 30px;height: 30px;background: rgb(141, 179, 226);line-height: 30px;color: rgb(255, 255, 255);font-size: 16px;font-style: italic;transform: rotate(0deg);\" data-original-title=\"\" title=\"\">1</section><section style=\"width: 30px;height: 30px;background: rgb(255, 199, 86);margin-left: 5px;margin-top: -25px;overflow: hidden;\"><br></section></section><section style=\"background-image: linear-gradient(to left, rgba(253, 123, 119, 0) 0%, rgb(255, 199, 86) 100%);height: 1px;flex: 1 1 0%;overflow: hidden;\"><br></section></section></section></section></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;text-align: center;\"><span style=\"color: rgb(0, 122, 170);\"><strong><span style=\"color: rgb(0, 122, 170);font-size: 16px;letter-spacing: 1px;\"><strong style=\"color: rgb(0, 122, 170);letter-spacing: 2px;text-align: left;white-space: normal;\"><span style=\"color: rgb(0, 122, 170);letter-spacing: 1px;font-size: 16px;\">什么是免疫细胞疗法？主要分哪些种类？主要用于治疗哪些疾病？</span></strong></span></strong></span><br></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"><br></span></section></section></section></section><section powered-by=\"xiumi.us\"><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">免疫细胞疗法是一种基于免疫细胞应答的新型精准靶向疗法，科学家通过采用细胞工程和基因工程等技术手段，刺激或者修饰来自人体</span><span style=\"font-size: 16px;letter-spacing: 1px;color: rgb(136, 136, 136);\">（自身或者捐助者）</span><span style=\"font-size: 16px;letter-spacing: 1px;\">的特定免疫细胞来实现疾病的治疗。</span></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"><br></span></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">根据调节免疫系统的策略不同，免疫细胞疗法可分为<strong>激活免疫疗法</strong>和<strong>抑制免疫疗法</strong>两种。</span></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"><br></span></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">目前临床上主要用于治疗癌症、传染性疾病以及自身免疫性疾病等。在癌症治疗领域里常使用的免疫细胞疗法属于激活免疫疗法，根据靶向调节的免疫细胞种类不同，免疫细胞可进一步分为T细胞 </span><span style=\"font-size: 16px;letter-spacing: 1px;color: rgb(136, 136, 136);\">（例如非常火爆的嵌合抗原受体T细胞免疫疗法CAR-T）</span><span style=\"font-size: 16px;letter-spacing: 1px;\">，T调节细胞，B细胞，树突状细胞</span><span style=\"font-size: 16px;letter-spacing: 1px;color: rgb(136, 136, 136);\">（DC, Dendritic Cell）</span><span style=\"font-size: 16px;letter-spacing: 1px;\">，自然杀伤细胞</span><span style=\"font-size: 16px;letter-spacing: 1px;color: rgb(136, 136, 136);\">（NK, Natural Killer）</span><span style=\"font-size: 16px;letter-spacing: 1px;\">等免疫细胞疗法。</span></section><p style=\"margin-left: 16px;margin-right: 16px;line-height: 3em;\"><br></p></section><section powered-by=\"xiumi.us\"><section><section powered-by=\"xiumi.us\"><section data-role=\"outer\" label=\"Powered by 135editor.com\"><section data-tools=\"135编辑器\" data-id=\"102525\" data-width=\"95%\" style=\"margin-left: auto;margin-right: auto;width: 95%;flex: 0 0 95%;\"><section style=\"margin: 10px auto;text-align: center;\"><section style=\"display: flex;justify-content: center;align-items: center;\" hm_fix=\"232:390\"><section style=\"background-image: linear-gradient(to right, rgba(253, 123, 119, 0) 0%, rgb(141, 179, 226) 100%);height: 1px;margin-left: 6px;flex: 1 1 0%;overflow: hidden;\"><br></section><section style=\"margin-right: 10px;margin-left: 10px;\"><section style=\"width: 30px;height: 30px;background: rgb(141, 179, 226);line-height: 30px;color: rgb(255, 255, 255);font-size: 16px;font-style: italic;transform: rotate(0deg);\" data-original-title=\"\" title=\"\">2</section><section style=\"width: 30px;height: 30px;background: rgb(255, 199, 86);margin-left: 5px;margin-top: -25px;overflow: hidden;\"><br></section></section><section style=\"background-image: linear-gradient(to left, rgba(253, 123, 119, 0) 0%, rgb(255, 199, 86) 100%);height: 1px;flex: 1 1 0%;overflow: hidden;\"><br></section></section></section></section></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;text-align: center;\"><span style=\"color: rgb(0, 122, 170);\"><strong><span style=\"color: rgb(0, 122, 170);font-size: 16px;letter-spacing: 1px;\">免疫细胞疗法治疗癌症的基本原理是什么？是否已经得到了临床验证？</span></strong></span><br></section><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.5em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"><br></span></p></section></section></section><section powered-by=\"xiumi.us\"><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">我们知道免疫系统不仅参与机体抵御病原入侵，同时也参与清除自身非正常细胞和相关产物。机体中的免疫细胞可识别正常细胞之外的物质</span><span style=\"font-size: 16px;letter-spacing: 1px;color: rgb(136, 136, 136);\">（如抗原，癌细胞，病毒）</span><span style=\"font-size: 16px;letter-spacing: 1px;\">，继而诱发免疫反应，启动免疫攻击，清除病原。免疫细胞疗法就是基于这个基本免疫学原理设计的。</span></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><br></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">科学家通过细胞工程和基因工程技术手段，改变免疫细胞的多个能力用于治疗癌症，其中包括：<strong>可提高免疫细胞识别癌细胞的能力，提高免疫细胞杀伤癌细胞能力，清除癌细胞对免疫细胞的抑制等。</strong>由于用于治疗癌症的免疫T细胞具有记忆能力且可以扩增，因此该使用该疗法的病人便获得了可长期杀害该肿瘤癌细胞的能力。</span></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><br></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">但是有一点需要注意，我们体内免疫细胞的攻击性非常强大，它们不仅能杀死癌细胞，也能杀死某些正常细胞，促进免疫系统释放大量的免疫因子，所以免疫细胞疗法所产生的副作用也正在于此，常见的表现方式包括免疫细胞因子释放综合征、对大脑神经毒性的副作用、B细胞数量减少等。</span></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><br></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><strong><span style=\"font-size: 16px;letter-spacing: 1px;\">目前已经有多个免疫细胞疗法被临床证实有效</span></strong><span style=\"font-size: 16px;letter-spacing: 1px;\">，例如CAR-T疗法在急性白血病的治疗上表现出了惊人的响应率</span><span style=\"font-size: 16px;letter-spacing: 1px;color: rgb(136, 136, 136);\">（90% - 100%）</span><span style=\"font-size: 16px;letter-spacing: 1px;\">。</span></section><p style=\"margin-left: 16px;margin-right: 16px;line-height: 3em;\"><br></p></section><section powered-by=\"xiumi.us\"><section><section powered-by=\"xiumi.us\"><section data-role=\"outer\" label=\"Powered by 135editor.com\"><section data-tools=\"135编辑器\" data-id=\"102525\" data-width=\"95%\" style=\"margin-left: auto;margin-right: auto;width: 95%;flex: 0 0 95%;\"><section style=\"margin: 10px auto;text-align: center;\"><section style=\"display: flex;justify-content: center;align-items: center;\" hm_fix=\"232:390\"><section style=\"background-image: linear-gradient(to right, rgba(253, 123, 119, 0) 0%, rgb(141, 179, 226) 100%);height: 1px;margin-left: 6px;flex: 1 1 0%;overflow: hidden;\"><br></section><section style=\"margin-right: 10px;margin-left: 10px;\"><section style=\"width: 30px;height: 30px;background: rgb(141, 179, 226);line-height: 30px;color: rgb(255, 255, 255);font-size: 16px;font-style: italic;transform: rotate(0deg);\" data-original-title=\"\" title=\"\">3</section><section style=\"width: 30px;height: 30px;background: rgb(255, 199, 86);margin-left: 5px;margin-top: -25px;overflow: hidden;\"><br></section></section><section style=\"background-image: linear-gradient(to left, rgba(253, 123, 119, 0) 0%, rgb(255, 199, 86) 100%);height: 1px;flex: 1 1 0%;overflow: hidden;\"><br></section></section></section></section></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;text-align: center;\"><span style=\"color: rgb(0, 122, 170);\"><strong><span style=\"color: rgb(0, 122, 170);font-size: 16px;letter-spacing: 1px;\">目前免疫细胞疗法治疗疾病处于何种阶段？有哪些是已经可以正式商用了？哪些还在测试阶段？效果如何？</span></strong></span><br></section><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.5em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"><br></span></p></section></section></section><section powered-by=\"xiumi.us\"><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">截至2021年，国际上已有5款CAR-T免疫细胞疗法通过美国FDA批准上市，分别用于治疗B细胞前体急性淋巴性白血病</span><span style=\"font-size: 16px;letter-spacing: 1px;color: rgb(136, 136, 136);\">（ALL）</span><span style=\"font-size: 16px;letter-spacing: 1px;\">、弥漫性大B细胞淋巴瘤</span><span style=\"font-size: 16px;letter-spacing: 1px;color: rgb(136, 136, 136);\">（DLBCL）</span><span style=\"font-size: 16px;letter-spacing: 1px;\">、复发/难治性多发性骨髓瘤</span><span style=\"font-size: 16px;letter-spacing: 1px;color: rgb(136, 136, 136);\">（r/r MM）</span><span style=\"font-size: 16px;letter-spacing: 1px;\">等血液肿瘤。</span></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><br></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">包括全球首个获批的CAR-T细胞疗法——诺华旗下用于治疗ALL和DLBCL的Kymriah；Gilead/Kite 公司的CAR-T细胞治疗药物 Yescarta</span><span style=\"font-size: 16px;letter-spacing: 1px;color: rgb(136, 136, 136);\">（用于治疗DLBC）</span><span style=\"font-size: 16px;letter-spacing: 1px;\">与 Tecartus</span><span style=\"font-size: 16px;letter-spacing: 1px;color: rgb(136, 136, 136);\">（用于治疗复发或难治性套细胞淋巴瘤，MCL）</span><span style=\"font-size: 16px;letter-spacing: 1px;\">；以及今年早些时候获批上市的百时美施贵宝</span><span style=\"font-size: 16px;letter-spacing: 1px;color: rgb(136, 136, 136);\">（BMS）</span><span style=\"font-size: 16px;letter-spacing: 1px;\">旗下公司开发的CAR-T疗法Breyanzi</span><span style=\"font-size: 16px;letter-spacing: 1px;color: rgb(136, 136, 136);\">（用于治疗DLBCL）</span><span style=\"font-size: 16px;letter-spacing: 1px;\">和Abecma</span><span style=\"font-size: 16px;letter-spacing: 1px;color: rgb(136, 136, 136);\">（用于治疗r/r MM）</span><span style=\"font-size: 16px;letter-spacing: 1px;\">等。根据披露的临床试验数据显示，对于DLBC的治疗效果统计如下。</span></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><br></section></section><section powered-by=\"xiumi.us\"><p style=\"line-height: 1.75em;padding: 0px 0.5em;margin-left: 8px;margin-right: 8px;\"><img data-ratio=\"0.3603744\" data-type=\"png\" data-w=\"641\" style=\"box-sizing: border-box; vertical-align: middle; width: 641px !important; visibility: visible !important; box-shadow: rgb(210, 210, 210) 0em 0em 0.5em 0px; font-size: 17px; max-width: 600px\" src=\"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_png/cyUibDfJJTsLu3ibSvvVmNBabkAnLK5ickh5tgibV7QXtSnQpUiaZbic9HGriaPOC6BLvXuicnhJUybgpuvIrEH8OrS10g/640?wx_fmt=png\"></p></section><section powered-by=\"xiumi.us\"><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><br></section></section><section powered-by=\"xiumi.us\"><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">国内首个CAR-T产品复星凯特的益基利仑赛注射液</span><span style=\"font-size: 16px;letter-spacing: 1px;color: rgb(136, 136, 136);\">（拟定，代号FKC876）</span><span style=\"font-size: 16px;letter-spacing: 1px;\">或有望于今年获批上市。由药明康德集团和美国巨诺</span><span style=\"font-size: 16px;letter-spacing: 1px;color: rgb(136, 136, 136);\">（Juno）</span><span style=\"font-size: 16px;letter-spacing: 1px;\">公司联合成立的 “药明巨诺生物科技有限公司” 所研发的CAR-T 治疗产品JWCAR029 ，主要用于治疗DLBCL也已于2019年完成临床二期效果良好。</span></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><br></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">然而，<strong>已获批的CAR-T免疫细胞疗法在治疗中也可能会出现严重副作用</strong>，常见的副作用可能包括细胞因子释放综合征</span><span style=\"font-size: 16px;letter-spacing: 1px;color: rgb(136, 136, 136);\">（CRS，细胞因子风暴诱发过度免疫应答，导致发热、低血压、心脏问题、呼吸困难、疲倦恶心以及凝血障碍等临床表现，严重时，会对身体组织和器官产生巨大损伤）</span><span style=\"font-size: 16px;letter-spacing: 1px;\">、神经系统毒性</span><span style=\"font-size: 16px;letter-spacing: 1px;color: rgb(136, 136, 136);\">（如头疼，疲劳、肌肉骨骼疼痛）</span><span style=\"font-size: 16px;letter-spacing: 1px;\">和长时间的B细胞减少等。</span></section><p style=\"margin-left: 16px;margin-right: 16px;line-height: 3em;\"><br></p></section><section powered-by=\"xiumi.us\"><section><section powered-by=\"xiumi.us\"><section data-role=\"outer\" label=\"Powered by 135editor.com\"><section data-tools=\"135编辑器\" data-id=\"102525\" data-width=\"95%\" style=\"margin-left: auto;margin-right: auto;width: 95%;flex: 0 0 95%;\"><section style=\"margin: 10px auto;text-align: center;\"><section style=\"display: flex;justify-content: center;align-items: center;\" hm_fix=\"232:390\"><section style=\"background-image: linear-gradient(to right, rgba(253, 123, 119, 0) 0%, rgb(141, 179, 226) 100%);height: 1px;margin-left: 6px;flex: 1 1 0%;overflow: hidden;\"><br></section><section style=\"margin-right: 10px;margin-left: 10px;\"><section style=\"width: 30px;height: 30px;background: rgb(141, 179, 226);line-height: 30px;color: rgb(255, 255, 255);font-size: 16px;font-style: italic;transform: rotate(0deg);\" data-original-title=\"\" title=\"\">4</section><section style=\"width: 30px;height: 30px;background: rgb(255, 199, 86);margin-left: 5px;margin-top: -25px;overflow: hidden;\"><br></section></section><section style=\"background-image: linear-gradient(to left, rgba(253, 123, 119, 0) 0%, rgb(255, 199, 86) 100%);height: 1px;flex: 1 1 0%;overflow: hidden;\"><br></section></section></section></section></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;text-align: center;\"><span style=\"color: rgb(0, 122, 170);\"><strong><span style=\"color: rgb(0, 122, 170);font-size: 16px;letter-spacing: 1px;\">北京大学第三医院医生张煜控诉的NK免疫细胞疗法是什么？主要用于治疗哪些疾病？效果如何？有哪些风险？</span></strong></span><br></section><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.5em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"><br></span></p></section></section></section><section powered-by=\"xiumi.us\"><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><strong><span style=\"font-size: 16px;letter-spacing: 1px;\">NK 免疫细胞疗法属于免疫细胞疗法之一，</span></strong><strong><span style=\"font-size: 16px;letter-spacing: 1px;\">是</span></strong><span style=\"font-size: 16px;letter-spacing: 1px;\"><strong>将修饰或改造过的自然杀伤细胞</strong></span><span style=\"font-size: 16px;letter-spacing: 1px;color: rgb(136, 136, 136);\">（Natural Killer细胞）</span><strong><span style=\"font-size: 16px;letter-spacing: 1px;\">注射到癌症患者体内，从而识别并杀死癌细胞。</span></strong><span style=\"font-size: 16px;letter-spacing: 1px;\">与CAR-T免疫细胞疗法不同的是，NK细胞属于天然免疫细胞种类，他不局限于特异性抗原，而是可识别任何非自身的物体并加以清除。因此NK免疫细胞疗法不仅可以采用基因工程手段改造后用于治疗，同时也可以不做任何修饰直接用于治疗癌症</span><span style=\"font-size: 16px;letter-spacing: 1px;color: rgb(136, 136, 136);\">（即可以直接从患者体内收集NK细胞，在体外进行扩增，激发，输回患者体内进行治疗）</span><span style=\"font-size: 16px;letter-spacing: 1px;\">。</span></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><br></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">此外NK免疫细胞疗法不会引起细胞因子释放综合征，移植物抗宿主病等CAR-T免疫细胞疗法需要面对的副作用。NK免疫细胞疗法也有短板，主要有NK 细胞在体内无法增生、在体内存活时间短、需要重复多次治疗。</span></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><br></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">然而，NK免疫细胞疗法依然处于早期研发阶段，全球多数该类型药物处于I期临床试验阶段。例如2021年4月13日，美国FDA授予正在进行I/II 期临床试验中的NK免疫细胞疗法CYNK-001孤儿药资格</span><span style=\"font-size: 16px;letter-spacing: 1px;color: rgb(136, 136, 136);\">（并非FDA认证大规模上市，而是用于患病人数为0.65‰~1‰的罕见病治疗）</span><span style=\"font-size: 16px;letter-spacing: 1px;\">，以用于治疗恶性神经胶质瘤患者。CYNK-001是首个未经基因修饰的人胚胎造血干细胞源性自然杀伤</span><span style=\"font-size: 16px;letter-spacing: 1px;color: rgb(136, 136, 136);\">（NK）</span><span style=\"font-size: 16px;letter-spacing: 1px;\">免疫细胞疗法。</span></section><p style=\"margin-left: 16px;margin-right: 16px;line-height: 3em;\"><br></p></section><section powered-by=\"xiumi.us\"><section><section powered-by=\"xiumi.us\"><section data-role=\"outer\" label=\"Powered by 135editor.com\"><section data-tools=\"135编辑器\" data-id=\"102525\" data-width=\"95%\" style=\"margin-left: auto;margin-right: auto;width: 95%;flex: 0 0 95%;\"><section style=\"margin: 10px auto;text-align: center;\"><section style=\"display: flex;justify-content: center;align-items: center;\" hm_fix=\"232:390\"><section style=\"background-image: linear-gradient(to right, rgba(253, 123, 119, 0) 0%, rgb(141, 179, 226) 100%);height: 1px;margin-left: 6px;flex: 1 1 0%;overflow: hidden;\"><br></section><section style=\"margin-right: 10px;margin-left: 10px;\"><section style=\"width: 30px;height: 30px;background: rgb(141, 179, 226);line-height: 30px;color: rgb(255, 255, 255);font-size: 16px;font-style: italic;transform: rotate(0deg);\" data-original-title=\"\" title=\"\">5</section><section style=\"width: 30px;height: 30px;background: rgb(255, 199, 86);margin-left: 5px;margin-top: -25px;overflow: hidden;\"><br></section></section><section style=\"background-image: linear-gradient(to left, rgba(253, 123, 119, 0) 0%, rgb(255, 199, 86) 100%);height: 1px;flex: 1 1 0%;overflow: hidden;\"><br></section></section></section></section></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;text-align: center;\"><span style=\"color: rgb(0, 122, 170);\"><strong><span style=\"color: rgb(0, 122, 170);font-size: 16px;letter-spacing: 1px;\">当年患者魏则西用的免疫细胞疗法是哪个种类？五年过去了，这种疗法是否获得了广泛认可？</span></strong></span><br></section><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.5em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"><br></span></p></section></section></section><section powered-by=\"xiumi.us\"><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">魏则西生前接受的免疫细胞疗法系 “DC-CIK生物免疫疗法”，即从病人体内采集树突状细胞</span><span style=\"font-size: 16px;letter-spacing: 1px;color: rgb(136, 136, 136);\">（DC）</span><span style=\"font-size: 16px;letter-spacing: 1px;\">与细胞因子诱导的杀伤细胞</span><span style=\"font-size: 16px;letter-spacing: 1px;color: rgb(136, 136, 136);\">（CIK）</span><span style=\"font-size: 16px;letter-spacing: 1px;\">，进行体外培养和扩增后回输到病人体内混合治疗癌症的免疫疗法。该方法利用了树突状细胞DC可以对肿瘤相关抗原特异性识别，当它与细胞因子诱导的杀伤细胞</span><span style=\"font-size: 16px;letter-spacing: 1px;color: rgb(136, 136, 136);\">（CIK）</span><span style=\"font-size: 16px;letter-spacing: 1px;\">共同培养之后，两者共同作用特异性识别肿瘤细胞并诱导肿瘤细胞凋亡。该DC-CIK能够广泛性识别各种肿瘤细胞，对病种没有区别，具有广泛治疗癌症的应用潜力。</span></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><br></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">但是，目前仍未有DC-CIK免疫细胞疗法类型药物获批上市，仅有早期临床科学试验在实施。最近的一项综合了17个临床试验共计1416人的荟萃分析发现，化疗+DC-CIK免疫细胞治疗方案优于单独使用化疗方案，其客观缓解率高出1.5倍。然而该疗法仍无足够的证据支持其广泛推广，其安全性和有效性需要更多的临床研究进行评估认证。</span></section><p style=\"margin-left: 16px;margin-right: 16px;line-height: 3em;\"><br></p></section><section powered-by=\"xiumi.us\"><section><section powered-by=\"xiumi.us\"><section data-role=\"outer\" label=\"Powered by 135editor.com\"><section data-tools=\"135编辑器\" data-id=\"102525\" data-width=\"95%\" style=\"margin-left: auto;margin-right: auto;width: 95%;flex: 0 0 95%;\"><section style=\"margin: 10px auto;text-align: center;\"><section style=\"display: flex;justify-content: center;align-items: center;\" hm_fix=\"232:390\"><section style=\"background-image: linear-gradient(to right, rgba(253, 123, 119, 0) 0%, rgb(141, 179, 226) 100%);height: 1px;margin-left: 6px;flex: 1 1 0%;overflow: hidden;\"><br></section><section style=\"margin-right: 10px;margin-left: 10px;\"><section style=\"width: 30px;height: 30px;background: rgb(141, 179, 226);line-height: 30px;color: rgb(255, 255, 255);font-size: 16px;font-style: italic;transform: rotate(0deg);\" data-original-title=\"\" title=\"\">6</section><section style=\"width: 30px;height: 30px;background: rgb(255, 199, 86);margin-left: 5px;margin-top: -25px;overflow: hidden;\"><br></section></section><section style=\"background-image: linear-gradient(to left, rgba(253, 123, 119, 0) 0%, rgb(255, 199, 86) 100%);height: 1px;flex: 1 1 0%;overflow: hidden;\"><br></section></section></section></section></section></section><section powered-by=\"xiumi.us\"><section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;text-align: center;\"><span style=\"color: rgb(0, 122, 170);\"><strong><span style=\"color: rgb(0, 122, 170);font-size: 16px;letter-spacing: 1px;\">干细胞疗法与免疫细胞疗法有哪些异同？哪种治疗癌症的效果更明显？更安全？</span></strong></span></section><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.5em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"><br></span></p></section></section></section></section><section powered-by=\"xiumi.us\"><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">干细胞疗法</span><span style=\"font-size: 16px;letter-spacing: 1px;color: rgb(136, 136, 136);\">（Stem-cell therapy）</span><span style=\"font-size: 16px;letter-spacing: 1px;\">是利用干细胞具有万能分化和复制增生的能力，可以在体外进行培养、定向诱导分化，从而生产全新的、正常的、更年轻的细胞、组织甚至器官等，从而代替机体内异常或者失能的部分，帮助机体恢复功能。</span></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><br></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">不同于免疫细胞疗法的关键之处是，干细胞疗法是用于补充更新和修复机体中失能的组织细胞。而免疫细胞疗法是清理排除机体有害物质。然而现代干细胞疗法也逐渐被应用于免疫细胞疗法，因为干细胞可以被诱导分化为免疫细胞，而被用于下游的免疫细胞疗法。</span></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><br></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><strong><span style=\"font-size: 16px;letter-spacing: 1px;\">干细胞疗法通常不会直接用于大部分肿瘤的治疗</span></strong><span style=\"font-size: 16px;letter-spacing: 1px;\">，而是可以帮助肿瘤患者接受大剂量化疗和放疗后恢复生产血液干细胞的能力，改善预后。对少数的血液肿瘤，例如多发性骨髓瘤和多种白血病, 骨髓干细胞移植则具有直接的治疗效果，在临床上也常用到。</span></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><br></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><strong><span style=\"font-size: 16px;letter-spacing: 1px;\">干细胞疗法也有副作用</span></strong><span style=\"font-size: 16px;letter-spacing: 1px;\">，尤其是移植物抗宿主病，它是一类多器官综合征，表现为主要累及皮肤、胃肠道、肝、肺和黏膜表面的组织炎症和/或纤维化。不同肿瘤患者采用哪种疗法，需要详细咨询主治医师。近年来，成人干细胞疗法也展示其作为疾病治疗的潜力，逐渐成为药物研发热点。成人干细胞疗法其采用患者自身的体细胞，用基因编辑技术诱导其成为多能干细胞，分化后被用于治疗疾病。例如已有小规模早期临床试验研究，采用成人干细胞疗法治疗卵巢早衰。</span></section><p style=\"margin-left: 16px;margin-right: 16px;line-height: 3em;\"><br></p></section><section powered-by=\"xiumi.us\"><section><section powered-by=\"xiumi.us\"><section data-role=\"outer\" label=\"Powered by 135editor.com\"><section data-tools=\"135编辑器\" data-id=\"102525\" data-width=\"95%\" style=\"margin-left: auto;margin-right: auto;width: 95%;flex: 0 0 95%;\"><section style=\"margin: 10px auto;text-align: center;\"><section style=\"display: flex;justify-content: center;align-items: center;\" hm_fix=\"232:390\"><section style=\"background-image: linear-gradient(to right, rgba(253, 123, 119, 0) 0%, rgb(141, 179, 226) 100%);height: 1px;margin-left: 6px;flex: 1 1 0%;overflow: hidden;\"><br></section><section style=\"margin-right: 10px;margin-left: 10px;\"><section style=\"width: 30px;height: 30px;background: rgb(141, 179, 226);line-height: 30px;color: rgb(255, 255, 255);font-size: 16px;font-style: italic;transform: rotate(0deg);\" data-original-title=\"\" title=\"\">7</section><section style=\"width: 30px;height: 30px;background: rgb(255, 199, 86);margin-left: 5px;margin-top: -25px;overflow: hidden;\"><br></section></section><section style=\"background-image: linear-gradient(to left, rgba(253, 123, 119, 0) 0%, rgb(255, 199, 86) 100%);height: 1px;flex: 1 1 0%;overflow: hidden;\"><br></section></section></section></section></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;text-align: center;\"><span style=\"color: rgb(0, 122, 170);\"><strong><span style=\"color: rgb(0, 122, 170);font-size: 16px;letter-spacing: 1px;\">为何免疫细胞疗法的费用如此高昂？是哪些环节比较耗钱？</span></strong></span></section><p style=\"margin-left: 16px;margin-right: 16px;text-align: center;line-height: 1.5em;\"><strong><span style=\"color: rgb(23, 126, 168);\"><br></span></strong></p><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><br></section></section></section></section><section powered-by=\"xiumi.us\"><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">免疫细胞疗法费用高昂，主要在于该治疗方法有<strong>繁杂的环节和生产成本。</strong>如图中所示，无论是无修饰的免疫细胞疗法</span><span style=\"font-size: 16px;letter-spacing: 1px;color: rgb(136, 136, 136);\">（如NK免疫细胞疗法）</span><span style=\"font-size: 16px;letter-spacing: 1px;\">还是基因改造的免疫细胞疗法</span><span style=\"font-size: 16px;letter-spacing: 1px;color: rgb(136, 136, 136);\">（如CAR-T）</span><span style=\"font-size: 16px;letter-spacing: 1px;\">，均需要较常规医疗用药之外的关键环节，即对免疫细胞在实验室里进行体外分离，培养，扩增，甚至对细胞进行基因改造</span><span style=\"font-size: 16px;letter-spacing: 1px;color: rgb(136, 136, 136);\">（CAR-T）</span><span style=\"font-size: 16px;letter-spacing: 1px;\">，其过程会产生高昂的仪器设备和试剂费用，这时相对耗钱高的地方。</span></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><br></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">此外在采用例如CAR-T免疫细胞治疗法时，需要大量前期准备，包括化疗清除淋巴细胞，恢复阶段的各项指标检测</span><span style=\"font-size: 16px;letter-spacing: 1px;color: rgb(136, 136, 136);\">（如免疫细胞，CT扫描，X-光照射）</span><span style=\"font-size: 16px;letter-spacing: 1px;\">，副作用检查和处理，不少于2周住院观察等等。在我国，包括CAR-T、 NK、DC-CIK等不同类型的免疫细胞疗法依然在临床试验阶段，暂无获批上市医药产品，因此原则上时不能收取费用。</span></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><br></section></section><section powered-by=\"xiumi.us\"><p style=\"line-height: 1.75em;padding: 0px 0.5em;margin-left: 8px;margin-right: 8px;\"><img data-ratio=\"0.549142\" data-type=\"png\" data-w=\"641\" style=\"box-sizing: border-box; vertical-align: middle; width: 641px !important; visibility: visible !important; box-shadow: rgb(210, 210, 210) 0em 0em 0.5em 0px; font-size: 17px; max-width: 600px\" src=\"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_png/cyUibDfJJTsLu3ibSvvVmNBabkAnLK5ickh9aoicwSLsqicAtt4FAQxtTrVyoibYcfRhHnZPRTZZLzUXibrfmjHU325xg/640?wx_fmt=png\"></p></section><section powered-by=\"xiumi.us\"><p style=\"margin-left: 16px;margin-right: 16px;text-align: right;line-height: 1.5em;\"><span style=\"font-size: 12px;color: rgb(136, 136, 136);letter-spacing: 1px;\">（来源：《细胞》杂志）</span></p></section><section powered-by=\"xiumi.us\"><p style=\"margin-left: 16px;margin-right: 16px;line-height: 3em;\"><br></p></section><section powered-by=\"xiumi.us\"><section><section powered-by=\"xiumi.us\"><section data-role=\"outer\" label=\"Powered by 135editor.com\"><section data-tools=\"135编辑器\" data-id=\"102525\" data-width=\"95%\" style=\"margin-left: auto;margin-right: auto;width: 95%;flex: 0 0 95%;\"><section style=\"margin: 10px auto;text-align: center;\"><section style=\"display: flex;justify-content: center;align-items: center;\" hm_fix=\"232:390\"><section style=\"background-image: linear-gradient(to right, rgba(253, 123, 119, 0) 0%, rgb(141, 179, 226) 100%);height: 1px;margin-left: 6px;flex: 1 1 0%;overflow: hidden;\"><br></section><section style=\"margin-right: 10px;margin-left: 10px;\"><section style=\"width: 30px;height: 30px;background: rgb(141, 179, 226);line-height: 30px;color: rgb(255, 255, 255);font-size: 16px;font-style: italic;transform: rotate(0deg);\" data-original-title=\"\" title=\"\">8</section><section style=\"width: 30px;height: 30px;background: rgb(255, 199, 86);margin-left: 5px;margin-top: -25px;overflow: hidden;\"><br></section></section><section style=\"background-image: linear-gradient(to left, rgba(253, 123, 119, 0) 0%, rgb(255, 199, 86) 100%);height: 1px;flex: 1 1 0%;overflow: hidden;\"><br></section></section></section></section></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;text-align: center;\"><span style=\"color: rgb(0, 122, 170);\"><strong><span style=\"color: rgb(0, 122, 170);font-size: 16px;letter-spacing: 1px;\">2018年获得诺贝尔奖的免疫疗法，和各大医院推荐使用的免疫细胞疗法有哪些区别？是否已经可以正式使用？</span></strong></span><br></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"><br></span></section></section></section></section><section powered-by=\"xiumi.us\"><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">2018年 James P. Allison &amp; Tasuku Honjo 因在癌症免疫疗法中的卓越贡献而获得诺贝尔奖。他们所采用的癌症免疫疗法称为 “检查点抑制剂疗法”，也是目前最常用的免疫治疗方案，已被批准用于黑色素瘤、肾癌、头颈癌、膀胱癌等多种肿瘤的临床治疗。区别于免疫细胞疗法的关键点在于采用的是单克隆抗体技术而非活细胞，即针对T细胞上表达的免疫抑制受体分子CLTA-4或者PD1设计单克隆抗体，激活细胞毒性T细胞，杀死癌细胞。</span></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><br></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">2011年和2014年，CTLA-4抗体制成的药物 ipilimumab</span><span style=\"font-size: 16px;letter-spacing: 1px;color: rgb(136, 136, 136);\">（Yervoy）</span><span style=\"font-size: 16px;letter-spacing: 1px;\">和PD1单克隆抗体 Pembrolizumab</span><span style=\"font-size: 16px;letter-spacing: 1px;color: rgb(136, 136, 136);\">（Keytruda）</span><span style=\"font-size: 16px;letter-spacing: 1px;\">药物分别通过FDA批准上市，用于黑色素瘤的治疗。此外，Pembrolizumab 在其他实体瘤的治疗效果也令人振奋——2015年美国前总统卡特经过 <strong>Keytruda</strong></span><span style=\"font-size: 16px;letter-spacing: 1px;color: rgb(136, 136, 136);\">（PD1抗体）</span><span style=\"font-size: 16px;letter-spacing: 1px;\">免疫治疗，脑内的癌症消失，为PD1疗法增加了 “明星效应” 的光辉。</span></section><p style=\"margin-left: 16px;margin-right: 16px;line-height: 3em;\"><br></p></section><section powered-by=\"xiumi.us\"><section><section powered-by=\"xiumi.us\"><section data-role=\"outer\" label=\"Powered by 135editor.com\"><section data-tools=\"135编辑器\" data-id=\"102525\" data-width=\"95%\" style=\"margin-left: auto;margin-right: auto;width: 95%;flex: 0 0 95%;\"><section style=\"margin: 10px auto;text-align: center;\"><section style=\"display: flex;justify-content: center;align-items: center;\" hm_fix=\"232:390\"><section style=\"background-image: linear-gradient(to right, rgba(253, 123, 119, 0) 0%, rgb(141, 179, 226) 100%);height: 1px;margin-left: 6px;flex: 1 1 0%;overflow: hidden;\"><br></section><section style=\"margin-right: 10px;margin-left: 10px;\"><section style=\"width: 30px;height: 30px;background: rgb(141, 179, 226);line-height: 30px;color: rgb(255, 255, 255);font-size: 16px;font-style: italic;transform: rotate(0deg);\" data-original-title=\"\" title=\"\">9</section><section style=\"width: 30px;height: 30px;background: rgb(255, 199, 86);margin-left: 5px;margin-top: -25px;overflow: hidden;\"><br></section></section><section style=\"background-image: linear-gradient(to left, rgba(253, 123, 119, 0) 0%, rgb(255, 199, 86) 100%);height: 1px;flex: 1 1 0%;overflow: hidden;\"><br></section></section></section></section></section></section><section powered-by=\"xiumi.us\"><section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;text-align: center;\"><span style=\"color: rgb(0, 122, 170);\"><strong><span style=\"color: rgb(0, 122, 170);font-size: 16px;letter-spacing: 1px;\">医生推荐使用免疫细胞疗法的时候，有哪些坑要注意规避？</span></strong></span></section><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.5em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"><br></span></p></section></section></section></section><section powered-by=\"xiumi.us\"><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">癌症患者是否需要使用免疫细胞疗法，首先需要了解<strong>处于肿瘤病程的哪个阶段，是否已经接受了相关治疗。</strong>鉴于在我国免疫细胞疗法仍处于临床试验阶段，患者有自愿参与和退出临床试验的自由，同时对费用和相关的信息披露</span><span style=\"font-size: 16px;letter-spacing: 1px;color: rgb(136, 136, 136);\">（如潜在风险和副作用等）</span><span style=\"font-size: 16px;letter-spacing: 1px;\">具有知情权。关于二代测序服务，如果医生推荐的治疗方案里包含二代测序服务，可询问包含有哪些基因位点，是否可提供突变配套的靶向治疗药物方案，基因测序公司的资质和能力等。</span></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><br></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">另外患者对于医生推荐的免疫细胞疗法，可以通过国家药品监督管理局药品审评中心官网</span><span style=\"font-size: 16px;letter-spacing: 1px;color: rgb(136, 136, 136);\">（http://www.cde.org.cn/index.jsp）</span><span style=\"font-size: 16px;letter-spacing: 1px;\">查询相关信息，对于在国内的临床试验，可以在网站中 “药物临床试验登记与信息公示平台”</span><span style=\"font-size: 16px;letter-spacing: 1px;color: rgb(136, 136, 136);\">（http://www.chinadrugtrials.org.cn/）</span><span style=\"font-size: 16px;letter-spacing: 1px;\">页面查询，以确认该治疗方案是否已经注册并被批准开展相关临床试验，里面有关于试验状态，适应症等详情。例如，CAR-T药物JWCAR029查询的结果显示如下图。</span></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"><br></span></section><section style=\"text-align: center;padding: 0px 0.5em;margin-left: 8px;margin-right: 8px;\"><img class=\"rich_pages js_insertlocalimg\" data-ratio=\"0.55625\" data-s=\"300,640\" data-type=\"png\" data-w=\"960\" style=\"box-shadow: rgb(210, 210, 210) 0em 0em 0.5em 0px; font-size: 17px; max-width: 600px\" src=\"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_png/LHibUTtMHPRNtvz5A1gm8NxTXLPQMoXf0iatKAiciaco8nhW5LhHCpgqbWHiabBBaR7muhBLI4uGkbiaUQAlmk0QQLeg/640?wx_fmt=png\"></section><p style=\"margin-left: 16px;margin-right: 16px;line-height: 3em;\"><br><span style=\"font-size: 16px;letter-spacing: 1px;\"></span></p></section><section powered-by=\"xiumi.us\"><section><section powered-by=\"xiumi.us\"><section data-role=\"outer\" label=\"Powered by 135editor.com\"><section data-tools=\"135编辑器\" data-id=\"102525\" data-width=\"95%\" style=\"margin-left: auto;margin-right: auto;width: 95%;flex: 0 0 95%;\"><section style=\"margin: 10px auto;text-align: center;\"><section style=\"display: flex;justify-content: center;align-items: center;\" hm_fix=\"232:390\"><section style=\"background-image: linear-gradient(to right, rgba(253, 123, 119, 0) 0%, rgb(141, 179, 226) 100%);height: 1px;margin-left: 6px;flex: 1 1 0%;overflow: hidden;\"><br></section><section style=\"margin-right: 10px;margin-left: 10px;\"><section style=\"width: 30px;height: 30px;background: rgb(141, 179, 226);line-height: 30px;color: rgb(255, 255, 255);font-size: 16px;font-style: italic;transform: rotate(0deg);\" data-original-title=\"\" title=\"\">10</section><section style=\"width: 30px;height: 30px;background: rgb(255, 199, 86);margin-left: 5px;margin-top: -25px;overflow: hidden;\"><br></section></section><section style=\"background-image: linear-gradient(to left, rgba(253, 123, 119, 0) 0%, rgb(255, 199, 86) 100%);height: 1px;flex: 1 1 0%;overflow: hidden;\"><br></section></section></section></section></section></section><section powered-by=\"xiumi.us\"><section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;text-align: center;\"><span style=\"color: rgb(0, 122, 170);\"><strong><span style=\"color: rgb(0, 122, 170);font-size: 16px;letter-spacing: 1px;\">从治疗癌症的大方向上看，免疫细胞疗法是大势所趋吗？会成为主流治疗方案吗？</span></strong></span></section><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.5em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"><br></span></p></section></section></section></section><section powered-by=\"xiumi.us\"><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">癌症的治疗方法有 “外科手术”、“化学疗法”、“放射疗法” 以及今天讨论的包括免疫细胞疗法在内的 “免疫疗法”。<strong>由于癌症的复杂性，不同癌症的发生发展受多因素影响，其治疗方式呈现不同。</strong>免疫细胞疗法被视为<strong>最具潜力的癌症治疗方法</strong>，具有与传统治疗方法不同的特性，包括其能够根据需要进行个性化治疗。</span></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><br></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">随着基础免疫学、基因组学、基因工程技术和合成生物学方面的持续应用和进步，免疫细胞疗法抗击癌症的潜力得到极大的提升。然而由于肿瘤的复杂性和高度异质性，免疫细胞疗法仍然面临巨大的挑战，很长一段时间内将无法替代现行的癌症治疗手段成为主流抗癌方案，尤其是对实体瘤的治疗效果有限。</span></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><br></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">高效应、高安全性的下一代免疫细胞疗法或许可借助于其他生物医学工程技术的快速发展而研发成功，早日实现上市，这包括日新月异的基因编辑技术，体外诱导多能干细胞技术，合成生物学技术，细胞工程技术等。除研发和生产的挑战外，昂贵的价格或许会成为免疫细胞治疗方案广泛应用的另一关键因素。</span></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><br></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">尽管免疫细胞疗法在治疗癌症上取了令人瞩目的变革性的成就，燃起了众多科学家和患者对成功治愈癌症的希望，但我们还需要清晰的看到，<strong>真正意义上的治愈癌症还有很长的路要走。</strong>抗癌路，道阻且长，行则将至，行而不辍，未来可期。<strong style=\"font-family: -apple-system, BlinkMacSystemFont, \" helvetica neue sc sans gb yahei ui arial sans-serif normal rgb><strong style=\"letter-spacing: 0.544px;color: rgb(136, 136, 136);\"><span style=\"letter-spacing: 1px;color: rgb(202, 48, 25);\"><img class=\"rich_pages\" data-ratio=\"0.9782608695652174\" data-s=\"300,640\" data-type=\"png\" data-w=\"92\" style=\"font-family: -apple-system-font, BlinkMacSystemFont,; max-width: 600px\" helvetica neue sc sans gb yahei ui arial sans-serif rgb border-box visible src=\"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_png/LHibUTtMHPRM5Ud8d7rOrOJZmevzXI7jkWPQBKNS1T4U2CFbBsLHLZqKukUV52RiaDRiaVKuLnOshZeeEDWuDse3w/640?wx_fmt=png\"><span style=\"font-family: -apple-system-font, BlinkMacSystemFont, \" helvetica neue sc sans gb yahei ui arial sans-serif> </span></span></strong></strong></span></section><p style=\"margin-left: 16px;margin-right: 16px;line-height: normal;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"><strong style=\"font-family: -apple-system, BlinkMacSystemFont, \" helvetica neue sc sans gb yahei ui arial sans-serif normal rgb><strong style=\"letter-spacing: 0.544px;color: rgb(136, 136, 136);\"><span style=\"letter-spacing: 1px;color: rgb(202, 48, 25);\"><span style=\"font-family: -apple-system-font, BlinkMacSystemFont, \" helvetica neue sc sans gb yahei ui arial sans-serif><br></span></span></strong></strong></span></p><section data-role=\"outer\" label=\"Powered by 135editor.com\"><section data-role=\"paragraph\" style=\"border-width: 0px;border-style: none;border-color: initial;margin-left: auto;margin-right: auto;width: 96%;flex: 0 0 96%;\" data-id=\"93131\" data-tools=\"135编辑器\" data-width=\"96%\"><section style=\"margin: 15px;white-space: normal;\"><section style=\"line-height: 10px;color: inherit;border-top: 1px solid rgb(198, 198, 199);border-bottom: 1px solid rgb(198, 198, 199);margin-top: 10px;\"><section style=\"font-size: 40px;color: inherit;height: 8px;margin-left: 35%;width: 65%;background-color: rgb(254, 254, 254);margin-top: -1px;\" data-width=\"65%\"><span style=\"color: #c6c6c7;\">“</span></section><section style=\"margin: 5px 15px 20px;\"><section style=\"line-height: 1.75em;color: #595959;font-size: 14px;letter-spacing: 1.5px;\"><section style=\"line-height: 1.75em;text-align: center;\"><span style=\"color: rgb(255, 255, 255);background-color: rgb(136, 136, 136);font-size: 14px;\"><strong><span style=\"background-color: rgb(136, 136, 136);color: rgb(255, 255, 255);font-size: 14px;letter-spacing: 1px;\"> 作者简介 </span></strong></span></section><p style=\"line-height: 1.75em;margin-top: 10px;\"><span style=\"font-size: 14px;letter-spacing: 1px;color: rgb(136, 136, 136);\">甘蔚，腾讯新闻知识官，英国牛津大学遗传统计学研究员。</span></p></section></section><section style=\"font-size: 40px;background-color: rgb(254, 254, 254);color: inherit;text-align: right;height: 10px;margin-bottom: -8px;width: 65%;\" data-width=\"65%\"><span style=\"color: #c6c6c7;\">”</span></section></section></section></section></section><section style=\"margin-left: 16px;margin-right: 16px;margin-top: 10px;line-height: normal;\"><span style=\"font-size: 14px;letter-spacing: 1px;color: rgb(136, 136, 136);\"></span></section><p style=\"line-height: 1.5em;margin-left: 16px;margin-right: 16px;margin-top: 10px;\"><span style=\"font-size: 14px;letter-spacing: 1px;color: rgb(136, 136, 136);\">本文原载于《健康学人》，《知识分子》获权转载。</span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.5em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"><strong style=\"font-family: -apple-system, BlinkMacSystemFont, \" helvetica neue sc sans gb yahei ui arial sans-serif normal rgb><strong style=\"letter-spacing: 0.544px;color: rgb(136, 136, 136);\"><span style=\"letter-spacing: 1px;color: rgb(202, 48, 25);\"><span style=\"font-family: -apple-system-font, BlinkMacSystemFont, \" helvetica neue sc sans gb yahei ui arial sans-serif><br></span></span></strong></strong></span></p></section><section style=\"margin-right: 16px;margin-left: 16px;white-space: normal;font-family: -apple-system-font, BlinkMacSystemFont, \" helvetica neue sc sans gb yahei ui arial sans-serif right rgb normal><span style=\"color: rgb(123, 127, 131);font-size: 14px;\"><span style=\"color: rgb(136, 136, 136);letter-spacing: 0.54px;font-family: -apple-system-font, BlinkMacSystemFont, Arial, sans-serif;\">制版编辑 </span><span style=\"color: rgb(255, 76, 0);letter-spacing: 0.54px;font-family: -apple-system-font, BlinkMacSystemFont, Arial, sans-serif;\">| </span><span style=\"color: rgb(136, 136, 136);letter-spacing: 0.54px;font-family: -apple-system-font, BlinkMacSystemFont, Arial, sans-serif;\">卢卡斯</span></span></section><section label=\"Powered by 135editor.com\" data-role=\"outer\" style=\"white-space: normal;font-family: -apple-system-font, BlinkMacSystemFont, \" helvetica neue sc sans gb yahei ui arial sans-serif rgb><section data-role=\"paragraph\"><section data-role=\"paragraph\"><section data-id=\"95447\" data-width=\"96%\" data-tools=\"135编辑器\" style=\"margin-right: auto;margin-left: auto;width: 649.9px;\"><section data-width=\"100%\" style=\"margin: 1em auto;width: 649.9px;\"><section data-autoskip=\"1\" style=\"margin-top: -10px;padding: 1em;border-width: 1px;border-style: solid;border-color: rgb(255, 255, 255);color: rgb(255, 255, 255);line-height: 1.75em;letter-spacing: 1.5px;font-size: 14px;\"><section style=\"margin-right: 16px;margin-left: 16px;\"><br></section><section data-role=\"paragraph\"><section style=\"margin-right: 16px;margin-left: 16px;text-align: center;\"><img border=\"0\" class=\"__bg_gif\" data-ratio=\"0.08658008658008658\" data-type=\"gif\" data-w=\"462\" data-width=\"80%\" height=\"\" title=\"\" width=\"80%\" style=\"letter-spacing: 0.54px; box-sizing: border-box !important; visibility: visible !important; width: 470.31px !important; max-width: 600px\" src=\"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_gif/lBLXrFcccXFwZwrMI7x3Idm0WicwB4ibviaNqA7dU3PEVQZrafvvMVQV4muo1DuHlPLtLIAwFbMWic5VGyn7G1vIuQ/640?wx_fmt=gif\"></section></section></section></section></section></section></section></section><section style=\"margin-right: 16px;margin-left: 16px;white-space: normal;font-family: -apple-system-font, BlinkMacSystemFont, \" helvetica neue sc sans gb yahei ui arial sans-serif center rgb><a target=\"_blank\" href=\"http://mp.weixin.qq.com/s?__biz=MzIyNDA2NTI4Mg==&amp;mid=2655470124&amp;idx=1&amp;sn=e23483ab328011b872808639a04aa0df&amp;chksm=f3a74041c4d0c957bdf1332edf4fa04f834e66540894a863bc119370581070e1203164d86e15&amp;scene=21#wechat_redirect\" textvalue=\"你已选中了添加链接的内容\" data-itemshowtype=\"0\" tab=\"innerlink\" data-linktype=\"1\"><span class=\"js_jump_icon h5_image_link\" data-positionback=\"static\" style=\"top: auto;left: auto;margin: 0px;right: auto;bottom: auto;\"><img class=\"rich_pages\" data-cropselx1=\"0\" data-cropselx2=\"524\" data-cropsely1=\"0\" data-cropsely2=\"132\" data-ratio=\"0.25234375\" data-s=\"300,640\" data-type=\"jpeg\" data-w=\"1280\" style=\"border-width: 0px; border-style: initial; border-color: initial; border-radius: 12px; left: auto; top: auto; right: auto; bottom: auto; box-sizing: border-box !important; visibility: visible !important; width: 524px; height: 132px; margin: 0px; max-width: 600px\" src=\"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_jpg/LHibUTtMHPRNtvz5A1gm8NxTXLPQMoXf0K20dY3OoG2icZfeM8lDarp6R6MFTcIsn0Z5B3AGvcMYQTEQYDqic7bHg/640?wx_fmt=jpeg\"></span></a></section><section style=\"margin-right: 16px;margin-left: 16px;white-space: normal;font-family: -apple-system-font, BlinkMacSystemFont, \" helvetica neue sc sans gb yahei ui arial sans-serif center rgb><a target=\"_blank\" href=\"http://mp.weixin.qq.com/s?__biz=MzIyNDA2NTI4Mg==&amp;mid=2655434520&amp;idx=3&amp;sn=f7a90383af52db277a51b86bd7dc367d&amp;chksm=f3a6b575c4d13c632a1f0c589c0d806c62fbf242bf04b2c0bcdb6baea91a95eaa2ad11b5d765&amp;scene=21#wechat_redirect\" textvalue=\"你已选中了添加链接的内容\" data-itemshowtype=\"0\" tab=\"innerlink\" data-linktype=\"2\" hasload=\"1\" style=\"-webkit-tap-highlight-color: rgba(0, 0, 0, 0);cursor: pointer;\"></a><a target=\"_blank\" href=\"http://mp.weixin.qq.com/s?__biz=MzIyNDA2NTI4Mg==&amp;mid=2655406806&amp;idx=1&amp;sn=b8463953510e2087fd24ce3c35d2b242&amp;chksm=f3a648bbc4d1c1adb8d02095162b8977e1aed2af741d0c562d1de200e3b3722850fc1ac47ac2&amp;scene=21#wechat_redirect\" textvalue=\"你已选中了添加链接的内容\" data-itemshowtype=\"0\" tab=\"innerlink\" data-linktype=\"1\" hasload=\"1\" style=\"font-family: -apple-system-font, BlinkMacSystemFont, \" helvetica neue sc sans gb yahei ui arial sans-serif center normal rgba pointer><span class=\"js_jump_icon h5_image_link\" data-positionback=\"static\" style=\"line-height: 0;top: auto;left: auto;right: auto;bottom: auto;\"><img class=\"rich_pages\" data-cropselx1=\"0\" data-cropselx2=\"524\" data-cropsely1=\"0\" data-cropsely2=\"132\" data-ratio=\"0.25234375\" data-s=\"300,640\" data-type=\"jpeg\" data-w=\"1280\" style=\"border-width: 0px; border-style: initial; border-color: initial; border-radius: 12px; left: auto; top: auto; right: auto; bottom: auto; box-sizing: border-box !important; visibility: visible !important; width: 524px !important; max-width: 600px\" src=\"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_jpg/LHibUTtMHPROiaSPyQU4nvX1SticyiaWicGm8CtriaDBpibJtP1OEEognohfVzia6wfheLzibjEkg8Q13VF1jsVkItyKXvA/640?wx_fmt=jpeg\"></span></a><br></section><section style=\"margin-right: 16px;margin-left: 16px;white-space: normal;font-family: -apple-system-font, BlinkMacSystemFont, \" helvetica neue sc sans gb yahei ui arial sans-serif center normal rgb><a target=\"_blank\" href=\"http://mp.weixin.qq.com/s?__biz=MzIyNDA2NTI4Mg==&amp;mid=2655440980&amp;idx=1&amp;sn=ac0385ee52bc4e4be7a94ed0feba41ae&amp;chksm=f3a6d239c4d15b2f66f153c3c13182c319756b3d43591c486c8994f67830016f7cabc6e21ece&amp;scene=21#wechat_redirect\" textvalue=\"你已选中了添加链接的内容\" data-itemshowtype=\"11\" tab=\"innerlink\" data-linktype=\"2\" hasload=\"1\" style=\"-webkit-tap-highlight-color: rgba(0, 0, 0, 0);cursor: pointer;\"></a><a target=\"_blank\" href=\"http://mp.weixin.qq.com/s?__biz=MzIyNDA2NTI4Mg==&amp;mid=2655434520&amp;idx=3&amp;sn=f7a90383af52db277a51b86bd7dc367d&amp;chksm=f3a6b575c4d13c632a1f0c589c0d806c62fbf242bf04b2c0bcdb6baea91a95eaa2ad11b5d765&amp;scene=21#wechat_redirect\" textvalue=\"你已选中了添加链接的内容\" data-itemshowtype=\"0\" tab=\"innerlink\" data-linktype=\"1\" hasload=\"1\" style=\"font-family: -apple-system-font, BlinkMacSystemFont, \" helvetica neue sc sans gb yahei ui arial sans-serif center normal rgba pointer><span class=\"js_jump_icon h5_image_link\" data-positionback=\"static\" style=\"line-height: 0;top: auto;left: auto;right: auto;bottom: auto;\"><img class=\"rich_pages\" data-cropselx1=\"0\" data-cropselx2=\"516\" data-cropsely1=\"0\" data-cropsely2=\"130\" data-ratio=\"0.25133689839572193\" data-s=\"300,640\" data-type=\"jpeg\" data-w=\"748\" style=\"border-width: 0px; border-style: initial; border-color: initial; border-radius: 12px; left: auto; top: auto; right: auto; bottom: auto; box-sizing: border-box !important; visibility: visible !important; width: 517px !important; max-width: 600px\" src=\"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_jpg/LHibUTtMHPROiaSPyQU4nvX1SticyiaWicGm8oTD3mlltfmmu6Sa1VyUI84AIjt1eiar8QvHgcclsNZ5ZJuhCehO0HWw/640?wx_fmt=jpeg\"></span></a></section><section style=\"margin-right: 16px;margin-left: 16px;white-space: normal;font-family: -apple-system-font, BlinkMacSystemFont, \" helvetica neue sc sans gb yahei ui arial sans-serif right normal rgb><br></section><section data-role=\"paragraph\" style=\"white-space: normal;font-family: -apple-system-font, BlinkMacSystemFont, \" helvetica neue sc sans gb yahei ui arial sans-serif rgb><section label=\"Powered by 135editor.com\" data-role=\"outer\"><section data-role=\"paragraph\"><section label=\"Powered by 135editor.com\" data-role=\"outer\"><section label=\"Powered by 135editor.com\" data-role=\"outer\"><section data-id=\"95265\" data-tools=\"135编辑器\"><section data-width=\"100%\" style=\"width: 677px;text-align: center;\"><section style=\"background-position: center bottom;background-image: url(\" https: repeat-x inline-block><section data-brushtype=\"text\" style=\"padding-right: 12px;padding-bottom: 5px;padding-left: 12px;letter-spacing: 1.5px;font-size: 14px;\">END</section></section></section></section></section></section><p style=\"margin-top: 5px;text-align: center;line-height: 1.75em;letter-spacing: 1.5px;\"><br></p></section></section></section><section data-role=\"paragraph\" style=\"white-space: normal;font-family: -apple-system-font, BlinkMacSystemFont, \" helvetica neue sc sans gb yahei ui arial sans-serif rgb><section style=\"margin-right: 16px;margin-left: 16px;text-align: center;min-height: 1em;\"><img class=\"rich_pages __bg_gif\" data-cropselx1=\"0\" data-cropselx2=\"546\" data-cropsely1=\"0\" data-cropsely2=\"231\" data-ratio=\"0.42566510172143973\" data-s=\"300,640\" data-type=\"gif\" data-w=\"639\" style=\"box-shadow: rgb(170, 170, 170) 0px 0px 14px 0px; box-sizing: border-box !important; visibility: visible !important; width: 546px !important; max-width: 600px\" src=\"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_gif/LHibUTtMHPRM871k4diaCHnjTxWsaC0HGzZasyqmClIDyvbtm490myxgZ5uRf9RrksOo1rCnC1mLRtvHsAQA6aRw/640?wx_fmt=gif\"></section></section>\n                </div>\n\n    \n        <br>\n        <div id=\"js_toobar3\" class=\"rich_media_tool\">\n            <a target=\"_blank\" href=\"http://www.zhishifenzi.com/\" id=\"js_view_source\" class=\"media_tool_meta meta_primary\">阅读原文</a>\n        </div>\n    \n    <br>\n\n    \n        <a target=\"_blank\" href=\"http://mp.weixin.qq.com/s?__biz=MzIyNDA2NTI4Mg==&amp;mid=2655472507&amp;idx=2&amp;sn=48b5e37f64fd4b1747a5e33c54ccc8bf&amp;chksm=f3a74916c4d0c00037c48f272aba326ce5582ab41eb0c6905dabc02f24fc93d015e6ed1b4f8a&amp;scene=0#rd\" style=\"color: blue\" class=\"media_tool_meta meta_primary\">原文</a>\n        <br>\n    \n\n    \n\n    <img alt=\"\" width=\"1px\" height=\"1px\" class=\"\" style=\"width:1px;height:1px;display:none\" src=\"http://www.jintiankansha.me/rss_static/6337/JTUqoGtBpB\"></div></div>","descriptionType":"html","publishedDate":"Tue, 18 May 2021 07:29:00 +0000","feedId":1531,"bgimg":"http://content.sov5.cn/mmbiz_jpg/LHibUTtMHPRNtvz5A1gm8NxTXLPQMoXf0DLmDYriaoYbN5DVU0nFXL0E7njd47P0eARF0IQq5bUiadbtIkwOSIWSw?imageView2/1/w/600","linkMd5":"961fa44a0a3d9f053a24ad2e12e55620","destWidth":600,"destHeight":459,"sourceBytes":33882,"destBytes":27536,"author":"","articleImgCdnMap":{"http://content.sov5.cn/mmbiz_jpg/LHibUTtMHPRNtvz5A1gm8NxTXLPQMoXf0DLmDYriaoYbN5DVU0nFXL0E7njd47P0eARF0IQq5bUiadbtIkwOSIWSw?imageView2/1/w/600":null,"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_jpg/cyUibDfJJTsLu3ibSvvVmNBabkAnLK5ickhIiac5rIKPRyD5xv4Ee2I8fwVz2cm6azsocJLWcncDuj4xZicdXh6cQMA/640?wx_fmt=jpeg":"https://cdn.jsdelivr.net/gh/myreaderx25/cdn86@2020_2/2021/05/19/15-05-13-528_abe5105c38d24c6b.webp","http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_png/LHibUTtMHPRNtvz5A1gm8NxTXLPQMoXf0q4fyb0U0Ys019Hg3UNyJAohZPHHgko2LdopWCbdKTASAUywxFrx2WA/640?wx_fmt=png":"https://cdn.jsdelivr.net/gh/myreaderx8/cdn2@2020_5/2021/05/19/15-05-09-834_ad36f5ffb2c988b7.webp","http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_jpg/LHibUTtMHPRNtvz5A1gm8NxTXLPQMoXf0GicvfCbjohObvb5F0Z08lQZUz7RsDGuIruXKpqRibIVLPLPmib5K9XgJA/640?wx_fmt=jpeg":"https://cdn.jsdelivr.net/gh/myreaderx5oss/cdn21@2020_4/2021/05/19/15-05-07-848_85543936281a65ec.webp","http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_png/cyUibDfJJTsLu3ibSvvVmNBabkAnLK5ickh5tgibV7QXtSnQpUiaZbic9HGriaPOC6BLvXuicnhJUybgpuvIrEH8OrS10g/640?wx_fmt=png":"https://cdn.jsdelivr.net/gh/myreaderx10/cdn18@2020_4/2021/05/19/15-05-07-773_def223a2e6e73dd8.webp","http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_png/cyUibDfJJTsLu3ibSvvVmNBabkAnLK5ickh9aoicwSLsqicAtt4FAQxtTrVyoibYcfRhHnZPRTZZLzUXibrfmjHU325xg/640?wx_fmt=png":"https://cdn.jsdelivr.net/gh/myreaderx1/cdn97@2020_2/2021/05/19/15-05-31-307_57b1a39ae6f7d840.webp","http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_png/LHibUTtMHPRNtvz5A1gm8NxTXLPQMoXf0iatKAiciaco8nhW5LhHCpgqbWHiabBBaR7muhBLI4uGkbiaUQAlmk0QQLeg/640?wx_fmt=png":"https://cdn.jsdelivr.net/gh/myreaderx30/cdn7@2020_5/2021/05/19/15-05-07-948_4a161967ce22e3af.webp","http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_png/LHibUTtMHPRM5Ud8d7rOrOJZmevzXI7jkWPQBKNS1T4U2CFbBsLHLZqKukUV52RiaDRiaVKuLnOshZeeEDWuDse3w/640?wx_fmt=png":"https://cdn.jsdelivr.net/gh/myreaderx6/cdn31@2020_2/2021/05/19/15-05-14-111_8ae0aba223f05c44.webp","http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_gif/lBLXrFcccXFwZwrMI7x3Idm0WicwB4ibviaNqA7dU3PEVQZrafvvMVQV4muo1DuHlPLtLIAwFbMWic5VGyn7G1vIuQ/640?wx_fmt=gif":null,"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_jpg/LHibUTtMHPRNtvz5A1gm8NxTXLPQMoXf0K20dY3OoG2icZfeM8lDarp6R6MFTcIsn0Z5B3AGvcMYQTEQYDqic7bHg/640?wx_fmt=jpeg":"https://cdn.jsdelivr.net/gh/myreaderx22/cdn19@2020_3/2021/05/19/15-05-17-763_c807840c2bc24160.webp","http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_jpg/LHibUTtMHPROiaSPyQU4nvX1SticyiaWicGm8CtriaDBpibJtP1OEEognohfVzia6wfheLzibjEkg8Q13VF1jsVkItyKXvA/640?wx_fmt=jpeg":"https://cdn.jsdelivr.net/gh/myreaderx27/cdn30@2020_5/2021/05/19/15-05-12-602_d15fb6d73d28a7d0.webp","http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_jpg/LHibUTtMHPROiaSPyQU4nvX1SticyiaWicGm8oTD3mlltfmmu6Sa1VyUI84AIjt1eiar8QvHgcclsNZ5ZJuhCehO0HWw/640?wx_fmt=jpeg":"https://cdn.jsdelivr.net/gh/myreaderx12/cdn88@2020_4/2021/05/19/15-05-08-058_0d34d7e626949550.webp","http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_gif/LHibUTtMHPRM871k4diaCHnjTxWsaC0HGzZasyqmClIDyvbtm490myxgZ5uRf9RrksOo1rCnC1mLRtvHsAQA6aRw/640?wx_fmt=gif":"https://cdn.jsdelivr.net/gh/myreaderx21/cdn91@2020_2/2021/05/19/15-05-07-944_53230ba3aabf500c.webp","http://www.jintiankansha.me/rss_static/6337/JTUqoGtBpB":null},"publishedOrCreatedDate":1621436645789}],"record":{"createdTime":"2021-05-19 23:04:05","updatedTime":"2021-05-19 23:04:05","feedId":1531,"fetchDate":"Wed, 19 May 2021 15:04:05 +0000","fetchMs":578,"handleMs":33,"totalMs":86905,"newArticles":0,"totalArticles":5,"status":1,"type":0,"ip":"bc1eecef1292254c09de6c1e66b750f3","hostName":"europe69*","requestId":"c6af7884976c41ea9f368cb4201e79c4_1531","contentType":"application/rss+xml","totalBytes":265204,"bgimgsTotal":1,"bgimgsGithubTotal":0,"articlesImgsTotal":14,"articlesImgsGithubTotal":11,"successGithubMap":{"myreaderx8":1,"myreaderx25":1,"myreaderx27":1,"myreaderx6":1,"myreaderx10":1,"myreaderx21":1,"myreaderx22":1,"myreaderx12":1,"myreaderx1":1,"myreaderx30":1,"myreaderx5oss":1},"failGithubMap":{"myreaderx23":1,"myreaderx31":1}},"feed":{"createdTime":"2020-08-24 21:31:30","updatedTime":"2020-09-01 09:48:48","id":1531,"name":"知识分子","url":"http://feedmaker.kindle4rss.com/feeds/The-Intellectual.weixin.xml","subscriber":null,"website":null,"icon":"http://www.sogou.com/images/logo/new/favicon.ico?v=4","icon_jsdelivr":"https://cdn.jsdelivr.net/gh/myreaderx65/cdn45@2020_1/2020/09/01/01-48-33-569_d24121c9beed1de6.ico","description":"《知识分子》是由饶毅、鲁白、谢宇三位学者创办的移动新媒体平台，致力于关注科学、人文、思想。我们将兼容并包，时刻为渴望知识、独立思考的人努力，共享人类知识、共析现代思想、共建智趣中国。欢迎关注。","weekly":null,"link":null},"noPictureArticleList":[{"createdTime":"2021-05-19 23:05:31","updatedTime":"2021-05-19 23:05:31","id":null,"feedId":1531,"linkMd5":"961fa44a0a3d9f053a24ad2e12e55620"}],"tmpCommonImgCdnBytes":0,"tmpBodyImgCdnBytes":265204,"tmpBgImgCdnBytes":0,"extra4":{"start":1621436644751,"total":0,"statList":[{"spend":1006,"msg":"获取xml内容"},{"spend":33,"msg":"解释文章"},{"spend":0,"msg":"上传封面图到cdn"},{"spend":0,"msg":"修正封面图上传失败重新上传"},{"spend":24813,"msg":"正文链接上传到cdn"}]},"extra5":14,"extra6":14,"extra7ImgCdnFailResultVector":[null,{"code":1,"isDone":false,"source":"http://content.sov5.cn/mmbiz_jpg/LHibUTtMHPRNtvz5A1gm8NxTXLPQMoXf0DLmDYriaoYbN5DVU0nFXL0E7njd47P0eARF0IQq5bUiadbtIkwOSIWSw?imageView2/1/w/600","sourceStatusCode":200,"destWidth":600,"destHeight":459,"sourceBytes":33882,"destBytes":27536,"targetWebpQuality":75,"feedId":1531,"totalSpendMs":783,"convertSpendMs":11,"createdTime":"2021-05-19 23:05:06","host":"us-037*","referer":"http://weixin.sogou.com/weixin?type=2&query=%E7%9F%A5%E8%AF%86%E5%88%86%E5%AD%90+NK%E5%85%8D%E7%96%AB%E7%BB%86%E8%83%9E%E7%96%97%E6%B3%95%EF%BC%9A%E4%B8%BA%E4%BD%95%E6%B2%A6%E4%B8%BA%E7%99%8C%E7%97%87%E6%82%A3%E8%80%85%E7%9A%84%20%E2%80%9C%E8%B6%85%E7%BA%A7%E6%9D%80%E6%89%8B%E2%80%9D%EF%BC%9F","linkMd5ListStr":"961fa44a0a3d9f053a24ad2e12e55620,961fa44a0a3d9f053a24ad2e12e55620","rawMap":{"githubUrl":"https://api.github.com/repos/myreaderx31/cdn48/contents/2021/05/19/15-05-06-763_29e7a6af9ad35543.webp","resp":{"code":403,"msg":"Forbidden","body":"{\n  \"message\": \"API rate limit exceeded for user ID 69855631.\",\n  \"documentation_url\": \"https://docs.github.com/rest/overview/resources-in-the-rest-api#rate-limiting\"\n}\n","headerMap":{"access-control-allow-origin":["*"],"access-control-expose-headers":["ETag, Link, Location, Retry-After, X-GitHub-OTP, X-RateLimit-Limit, X-RateLimit-Remaining, X-RateLimit-Used, X-RateLimit-Resource, X-RateLimit-Reset, X-OAuth-Scopes, X-Accepted-OAuth-Scopes, X-Poll-Interval, X-GitHub-Media-Type, Deprecation, Sunset"],"content-security-policy":["default-src 'none'"],"content-type":["application/json; charset=utf-8"],"date":["Wed, 19 May 2021 15:05:06 GMT"],"referrer-policy":["origin-when-cross-origin, strict-origin-when-cross-origin"],"server":["GitHub.com"],"strict-transport-security":["max-age=31536000; includeSubdomains; preload"],"transfer-encoding":["chunked"],"vary":["Accept-Encoding, Accept, X-Requested-With"],"x-accepted-oauth-scopes":["repo"],"x-content-type-options":["nosniff"],"x-frame-options":["deny"],"x-github-media-type":["github.v3; format=json"],"x-github-request-id":["DA94:74D3:2F35B60:582010E:60A52922"],"x-oauth-scopes":["admin:enterprise, admin:gpg_key, admin:org, admin:org_hook, admin:public_key, admin:repo_hook, delete:packages, delete_repo, gist, notifications, repo, user, workflow, write:discussion, write:packages"],"x-ratelimit-limit":["60"],"x-ratelimit-remaining":["0"],"x-ratelimit-reset":["1621439750"],"x-ratelimit-resource":["core"],"x-ratelimit-used":["60"],"x-xss-protection":["0"]},"exceptionMsg":"Unexpected code 403,url is : https://api.github.com/repos/myreaderx31/cdn48/contents/2021/05/19/15-05-06-763_29e7a6af9ad35543.webp","historyStatusCode":[],"spendMs":39},"base64UserPassword":null,"token":"da243******************************d9e47"},"githubUser":"myreaderx31","githubHttpCode":403,"extra22GetBytesInfo":"1、没有Referer字段","extra23historyStatusCode":[200],"sourceSize":"33.1 KB","destSize":"26.9 KB","compressRate":"81.3%"},{"code":1,"isDone":false,"source":"http://www.jintiankansha.me/rss_static/6337/JTUqoGtBpB","sourceStatusCode":405,"sourceBytes":0,"destBytes":0,"feedId":1531,"totalSpendMs":558,"convertSpendMs":0,"createdTime":"2021-05-19 23:05:06","host":"us-006*","referer":"http://weixin.sogou.com/weixin?type=2&query=%E7%9F%A5%E8%AF%86%E5%88%86%E5%AD%90+NK%E5%85%8D%E7%96%AB%E7%BB%86%E8%83%9E%E7%96%97%E6%B3%95%EF%BC%9A%E4%B8%BA%E4%BD%95%E6%B2%A6%E4%B8%BA%E7%99%8C%E7%97%87%E6%82%A3%E8%80%85%E7%9A%84%20%E2%80%9C%E8%B6%85%E7%BA%A7%E6%9D%80%E6%89%8B%E2%80%9D%EF%BC%9F","linkMd5ListStr":"961fa44a0a3d9f053a24ad2e12e55620","extra22GetBytesInfo":"1、没有Referer字段","extra23historyStatusCode":[405],"sourceSize":"0","destSize":"0"},{"code":1,"isDone":false,"source":"http://www.jintiankansha.me/rss_static/6337/JTUqoGtBpB","sourceStatusCode":405,"sourceBytes":0,"destBytes":0,"feedId":1531,"totalSpendMs":741,"convertSpendMs":0,"createdTime":"2021-05-19 23:05:07","host":"us-022*","referer":"http://weixin.sogou.com/weixin?type=2&query=%E7%9F%A5%E8%AF%86%E5%88%86%E5%AD%90+NK%E5%85%8D%E7%96%AB%E7%BB%86%E8%83%9E%E7%96%97%E6%B3%95%EF%BC%9A%E4%B8%BA%E4%BD%95%E6%B2%A6%E4%B8%BA%E7%99%8C%E7%97%87%E6%82%A3%E8%80%85%E7%9A%84%20%E2%80%9C%E8%B6%85%E7%BA%A7%E6%9D%80%E6%89%8B%E2%80%9D%EF%BC%9F","linkMd5ListStr":"961fa44a0a3d9f053a24ad2e12e55620","extra22GetBytesInfo":"1、没有Referer字段","extra23historyStatusCode":[405],"sourceSize":"0","destSize":"0"},{"code":1,"isDone":false,"source":"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_gif/lBLXrFcccXFwZwrMI7x3Idm0WicwB4ibviaNqA7dU3PEVQZrafvvMVQV4muo1DuHlPLtLIAwFbMWic5VGyn7G1vIuQ/640?wx_fmt=gif","sourceStatusCode":200,"destWidth":462,"destHeight":40,"sourceBytes":68255,"destBytes":82152,"targetWebpQuality":75,"feedId":1531,"totalSpendMs":1887,"convertSpendMs":112,"createdTime":"2021-05-19 23:05:06","host":"europe-57*","referer":"http://weixin.sogou.com/weixin?type=2&query=%E7%9F%A5%E8%AF%86%E5%88%86%E5%AD%90+NK%E5%85%8D%E7%96%AB%E7%BB%86%E8%83%9E%E7%96%97%E6%B3%95%EF%BC%9A%E4%B8%BA%E4%BD%95%E6%B2%A6%E4%B8%BA%E7%99%8C%E7%97%87%E6%82%A3%E8%80%85%E7%9A%84%20%E2%80%9C%E8%B6%85%E7%BA%A7%E6%9D%80%E6%89%8B%E2%80%9D%EF%BC%9F","linkMd5ListStr":"961fa44a0a3d9f053a24ad2e12e55620","rawMap":{"githubUrl":"https://api.github.com/repos/myreaderx23/cdn14/contents/2021/05/19/15-05-08-490_bf9d412e67e73107.webp","resp":{"code":403,"msg":"Forbidden","body":"{\n  \"message\": \"API rate limit exceeded for user ID 69189253.\",\n  \"documentation_url\": \"https://docs.github.com/rest/overview/resources-in-the-rest-api#rate-limiting\"\n}\n","headerMap":{"access-control-allow-origin":["*"],"access-control-expose-headers":["ETag, Link, Location, Retry-After, X-GitHub-OTP, X-RateLimit-Limit, X-RateLimit-Remaining, X-RateLimit-Used, X-RateLimit-Resource, X-RateLimit-Reset, X-OAuth-Scopes, X-Accepted-OAuth-Scopes, X-Poll-Interval, X-GitHub-Media-Type, Deprecation, Sunset"],"content-security-policy":["default-src 'none'"],"content-type":["application/json; charset=utf-8"],"date":["Wed, 19 May 2021 15:05:08 GMT"],"referrer-policy":["origin-when-cross-origin, strict-origin-when-cross-origin"],"server":["GitHub.com"],"strict-transport-security":["max-age=31536000; includeSubdomains; preload"],"transfer-encoding":["chunked"],"vary":["Accept-Encoding, Accept, X-Requested-With"],"x-accepted-oauth-scopes":["repo"],"x-content-type-options":["nosniff"],"x-frame-options":["deny"],"x-github-media-type":["github.v3; format=json"],"x-github-request-id":["ED56:8DF4:9961E4D:9C377B9:60A52924"],"x-oauth-scopes":["admin:enterprise, admin:gpg_key, admin:org, admin:org_hook, admin:public_key, admin:repo_hook, delete:packages, delete_repo, gist, notifications, repo, user, workflow, write:discussion, write:packages"],"x-ratelimit-limit":["60"],"x-ratelimit-remaining":["0"],"x-ratelimit-reset":["1621439744"],"x-ratelimit-resource":["core"],"x-ratelimit-used":["60"],"x-xss-protection":["0"]},"exceptionMsg":"Unexpected code 403,url is : https://api.github.com/repos/myreaderx23/cdn14/contents/2021/05/19/15-05-08-490_bf9d412e67e73107.webp","historyStatusCode":[],"spendMs":259},"base64UserPassword":null,"token":"df0b9******************************93a6e"},"githubUser":"myreaderx23","githubHttpCode":403,"extra22GetBytesInfo":"1、没有Referer字段","extra23historyStatusCode":[200],"sourceSize":"66.7 KB","destSize":"80.2 KB","compressRate":"120.4%"},{"code":1,"isDone":false,"source":"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_gif/lBLXrFcccXFwZwrMI7x3Idm0WicwB4ibviaNqA7dU3PEVQZrafvvMVQV4muo1DuHlPLtLIAwFbMWic5VGyn7G1vIuQ/640?wx_fmt=gif","sourceStatusCode":200,"destWidth":462,"destHeight":40,"sourceBytes":68255,"destBytes":82152,"targetWebpQuality":75,"feedId":1531,"totalSpendMs":1116,"convertSpendMs":105,"createdTime":"2021-05-19 23:05:08","host":"us-011*","referer":"http://weixin.sogou.com/weixin?type=2&query=%E7%9F%A5%E8%AF%86%E5%88%86%E5%AD%90+NK%E5%85%8D%E7%96%AB%E7%BB%86%E8%83%9E%E7%96%97%E6%B3%95%EF%BC%9A%E4%B8%BA%E4%BD%95%E6%B2%A6%E4%B8%BA%E7%99%8C%E7%97%87%E6%82%A3%E8%80%85%E7%9A%84%20%E2%80%9C%E8%B6%85%E7%BA%A7%E6%9D%80%E6%89%8B%E2%80%9D%EF%BC%9F","linkMd5ListStr":"961fa44a0a3d9f053a24ad2e12e55620","rawMap":{"githubUrl":"https://api.github.com/repos/myreaderx23/cdn14/contents/2021/05/19/15-05-09-925_bf9d412e67e73107.webp","resp":{"code":403,"msg":"Forbidden","body":"{\n  \"message\": \"API rate limit exceeded for user ID 69189253.\",\n  \"documentation_url\": \"https://docs.github.com/rest/overview/resources-in-the-rest-api#rate-limiting\"\n}\n","headerMap":{"access-control-allow-origin":["*"],"access-control-expose-headers":["ETag, Link, Location, Retry-After, X-GitHub-OTP, X-RateLimit-Limit, X-RateLimit-Remaining, X-RateLimit-Used, X-RateLimit-Resource, X-RateLimit-Reset, X-OAuth-Scopes, X-Accepted-OAuth-Scopes, X-Poll-Interval, X-GitHub-Media-Type, Deprecation, Sunset"],"content-security-policy":["default-src 'none'"],"content-type":["application/json; charset=utf-8"],"date":["Wed, 19 May 2021 15:05:09 GMT"],"referrer-policy":["origin-when-cross-origin, strict-origin-when-cross-origin"],"server":["GitHub.com"],"strict-transport-security":["max-age=31536000; includeSubdomains; preload"],"transfer-encoding":["chunked"],"vary":["Accept-Encoding, Accept, X-Requested-With"],"x-accepted-oauth-scopes":["repo"],"x-content-type-options":["nosniff"],"x-frame-options":["deny"],"x-github-media-type":["github.v3; format=json"],"x-github-request-id":["C01C:1EC7:1C8367A:5CB3809:60A52925"],"x-oauth-scopes":["admin:enterprise, admin:gpg_key, admin:org, admin:org_hook, admin:public_key, admin:repo_hook, delete:packages, delete_repo, gist, notifications, repo, user, workflow, write:discussion, write:packages"],"x-ratelimit-limit":["60"],"x-ratelimit-remaining":["0"],"x-ratelimit-reset":["1621439744"],"x-ratelimit-resource":["core"],"x-ratelimit-used":["60"],"x-xss-protection":["0"]},"exceptionMsg":"Unexpected code 403,url is : https://api.github.com/repos/myreaderx23/cdn14/contents/2021/05/19/15-05-09-925_bf9d412e67e73107.webp","historyStatusCode":[],"spendMs":49},"base64UserPassword":null,"token":"df0b9******************************93a6e"},"githubUser":"myreaderx23","githubHttpCode":403,"extra22GetBytesInfo":"1、没有Referer字段","extra23historyStatusCode":[200],"sourceSize":"66.7 KB","destSize":"80.2 KB","compressRate":"120.4%"}],"extra10_invalidATagHrefValue":{},"extra111_proxyServerAndStatMap":{"http://us-53.herokuapp.com/":{"failCount":0,"successCount":1,"resultList":[200]},"http://europe68.herokuapp.com/":{"failCount":0,"successCount":1,"resultList":[200]},"http://us-005.herokuapp.com/":{"failCount":0,"successCount":1,"resultList":[200]},"http://europe61.herokuapp.com/":{"failCount":0,"successCount":1,"resultList":[200]},"http://us-022.herokuapp.com/":{"failCount":1,"successCount":0,"resultList":[405]},"http://us-009.herokuapp.com/":{"failCount":0,"successCount":1,"resultList":[200]},"http://europe-60.herokuapp.com/":{"failCount":0,"successCount":1,"resultList":[200]},"http://us-52.herokuapp.com/":{"failCount":0,"successCount":1,"resultList":[200]},"http://europe70.herokuapp.com/":{"failCount":0,"successCount":1,"resultList":[200]},"http://us-011.herokuapp.com/":{"failCount":0,"successCount":2,"resultList":[200,200]},"http://us-006.herokuapp.com/":{"failCount":1,"successCount":0,"resultList":[405]},"http://europe-57.herokuapp.com/":{"failCount":0,"successCount":1,"resultList":[200]},"http://europe64.herokuapp.com/":{"failCount":0,"successCount":1,"resultList":[200]},"http://us-010.herokuapp.com/":{"failCount":0,"successCount":1,"resultList":[200]}},"extra12ImgCdnSuccessResultVector":[{"code":1,"isDone":false,"source":"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_png/cyUibDfJJTsLu3ibSvvVmNBabkAnLK5ickh5tgibV7QXtSnQpUiaZbic9HGriaPOC6BLvXuicnhJUybgpuvIrEH8OrS10g/640?wx_fmt=png","sourceStatusCode":200,"destWidth":641,"destHeight":231,"fixedGithubDest":"https://cdn.jsdelivr.net/gh/myreaderx10/cdn18@2020_4/2021/05/19/15-05-07-773_def223a2e6e73dd8.webp","sourceBytes":20285,"destBytes":14934,"targetWebpQuality":75,"feedId":1531,"totalSpendMs":1134,"convertSpendMs":7,"createdTime":"2021-05-19 23:05:06","host":"us-009*","referer":"http://weixin.sogou.com/weixin?type=2&query=%E7%9F%A5%E8%AF%86%E5%88%86%E5%AD%90+NK%E5%85%8D%E7%96%AB%E7%BB%86%E8%83%9E%E7%96%97%E6%B3%95%EF%BC%9A%E4%B8%BA%E4%BD%95%E6%B2%A6%E4%B8%BA%E7%99%8C%E7%97%87%E6%82%A3%E8%80%85%E7%9A%84%20%E2%80%9C%E8%B6%85%E7%BA%A7%E6%9D%80%E6%89%8B%E2%80%9D%EF%BC%9F","linkMd5ListStr":"961fa44a0a3d9f053a24ad2e12e55620","githubUser":"myreaderx10","githubHttpCode":201,"extra22GetBytesInfo":"1、没有Referer字段","extra23historyStatusCode":[200],"sourceSize":"19.8 KB","destSize":"14.6 KB","compressRate":"73.6%"},{"code":1,"isDone":false,"source":"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_jpg/LHibUTtMHPRNtvz5A1gm8NxTXLPQMoXf0GicvfCbjohObvb5F0Z08lQZUz7RsDGuIruXKpqRibIVLPLPmib5K9XgJA/640?wx_fmt=jpeg","sourceStatusCode":200,"destWidth":621,"destHeight":419,"fixedGithubDest":"https://cdn.jsdelivr.net/gh/myreaderx5oss/cdn21@2020_4/2021/05/19/15-05-07-848_85543936281a65ec.webp","sourceBytes":29895,"destBytes":24678,"targetWebpQuality":75,"feedId":1531,"totalSpendMs":1229,"convertSpendMs":9,"createdTime":"2021-05-19 23:05:06","host":"us-011*","referer":"http://weixin.sogou.com/weixin?type=2&query=%E7%9F%A5%E8%AF%86%E5%88%86%E5%AD%90+NK%E5%85%8D%E7%96%AB%E7%BB%86%E8%83%9E%E7%96%97%E6%B3%95%EF%BC%9A%E4%B8%BA%E4%BD%95%E6%B2%A6%E4%B8%BA%E7%99%8C%E7%97%87%E6%82%A3%E8%80%85%E7%9A%84%20%E2%80%9C%E8%B6%85%E7%BA%A7%E6%9D%80%E6%89%8B%E2%80%9D%EF%BC%9F","linkMd5ListStr":"961fa44a0a3d9f053a24ad2e12e55620","githubUser":"myreaderx5oss","githubHttpCode":201,"extra22GetBytesInfo":"1、没有Referer字段","extra23historyStatusCode":[200],"sourceSize":"29.2 KB","destSize":"24.1 KB","compressRate":"82.5%"},{"code":1,"isDone":false,"source":"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_gif/LHibUTtMHPRM871k4diaCHnjTxWsaC0HGzZasyqmClIDyvbtm490myxgZ5uRf9RrksOo1rCnC1mLRtvHsAQA6aRw/640?wx_fmt=gif","sourceStatusCode":200,"destWidth":639,"destHeight":272,"fixedGithubDest":"https://cdn.jsdelivr.net/gh/myreaderx21/cdn91@2020_2/2021/05/19/15-05-07-944_53230ba3aabf500c.webp","sourceBytes":26623,"destBytes":12888,"targetWebpQuality":75,"feedId":1531,"totalSpendMs":1289,"convertSpendMs":29,"createdTime":"2021-05-19 23:05:06","host":"us-53*","referer":"http://weixin.sogou.com/weixin?type=2&query=%E7%9F%A5%E8%AF%86%E5%88%86%E5%AD%90+NK%E5%85%8D%E7%96%AB%E7%BB%86%E8%83%9E%E7%96%97%E6%B3%95%EF%BC%9A%E4%B8%BA%E4%BD%95%E6%B2%A6%E4%B8%BA%E7%99%8C%E7%97%87%E6%82%A3%E8%80%85%E7%9A%84%20%E2%80%9C%E8%B6%85%E7%BA%A7%E6%9D%80%E6%89%8B%E2%80%9D%EF%BC%9F","linkMd5ListStr":"961fa44a0a3d9f053a24ad2e12e55620","githubUser":"myreaderx21","githubHttpCode":201,"extra22GetBytesInfo":"1、没有Referer字段","extra23historyStatusCode":[200],"sourceSize":"26 KB","destSize":"12.6 KB","compressRate":"48.4%"},{"code":1,"isDone":false,"source":"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_jpg/LHibUTtMHPROiaSPyQU4nvX1SticyiaWicGm8oTD3mlltfmmu6Sa1VyUI84AIjt1eiar8QvHgcclsNZ5ZJuhCehO0HWw/640?wx_fmt=jpeg","sourceStatusCode":200,"destWidth":748,"destHeight":188,"fixedGithubDest":"https://cdn.jsdelivr.net/gh/myreaderx12/cdn88@2020_4/2021/05/19/15-05-08-058_0d34d7e626949550.webp","sourceBytes":31649,"destBytes":25746,"targetWebpQuality":75,"feedId":1531,"totalSpendMs":1379,"convertSpendMs":7,"createdTime":"2021-05-19 23:05:06","host":"us-52*","referer":"http://weixin.sogou.com/weixin?type=2&query=%E7%9F%A5%E8%AF%86%E5%88%86%E5%AD%90+NK%E5%85%8D%E7%96%AB%E7%BB%86%E8%83%9E%E7%96%97%E6%B3%95%EF%BC%9A%E4%B8%BA%E4%BD%95%E6%B2%A6%E4%B8%BA%E7%99%8C%E7%97%87%E6%82%A3%E8%80%85%E7%9A%84%20%E2%80%9C%E8%B6%85%E7%BA%A7%E6%9D%80%E6%89%8B%E2%80%9D%EF%BC%9F","linkMd5ListStr":"961fa44a0a3d9f053a24ad2e12e55620","githubUser":"myreaderx12","githubHttpCode":201,"extra22GetBytesInfo":"1、没有Referer字段","extra23historyStatusCode":[200],"sourceSize":"30.9 KB","destSize":"25.1 KB","compressRate":"81.3%"},{"code":1,"isDone":false,"source":"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_png/LHibUTtMHPRNtvz5A1gm8NxTXLPQMoXf0iatKAiciaco8nhW5LhHCpgqbWHiabBBaR7muhBLI4uGkbiaUQAlmk0QQLeg/640?wx_fmt=png","sourceStatusCode":200,"destWidth":960,"destHeight":534,"fixedGithubDest":"https://cdn.jsdelivr.net/gh/myreaderx30/cdn7@2020_5/2021/05/19/15-05-07-948_4a161967ce22e3af.webp","sourceBytes":88436,"destBytes":49202,"targetWebpQuality":75,"feedId":1531,"totalSpendMs":1618,"convertSpendMs":24,"createdTime":"2021-05-19 23:05:06","host":"europe70*","referer":"http://weixin.sogou.com/weixin?type=2&query=%E7%9F%A5%E8%AF%86%E5%88%86%E5%AD%90+NK%E5%85%8D%E7%96%AB%E7%BB%86%E8%83%9E%E7%96%97%E6%B3%95%EF%BC%9A%E4%B8%BA%E4%BD%95%E6%B2%A6%E4%B8%BA%E7%99%8C%E7%97%87%E6%82%A3%E8%80%85%E7%9A%84%20%E2%80%9C%E8%B6%85%E7%BA%A7%E6%9D%80%E6%89%8B%E2%80%9D%EF%BC%9F","linkMd5ListStr":"961fa44a0a3d9f053a24ad2e12e55620","githubUser":"myreaderx30","githubHttpCode":201,"extra22GetBytesInfo":"1、没有Referer字段","extra23historyStatusCode":[200],"sourceSize":"86.4 KB","destSize":"48 KB","compressRate":"55.6%"},{"code":1,"isDone":false,"source":"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_png/LHibUTtMHPRNtvz5A1gm8NxTXLPQMoXf0q4fyb0U0Ys019Hg3UNyJAohZPHHgko2LdopWCbdKTASAUywxFrx2WA/640?wx_fmt=png","sourceStatusCode":200,"destWidth":51,"destHeight":65,"fixedGithubDest":"https://cdn.jsdelivr.net/gh/myreaderx8/cdn2@2020_5/2021/05/19/15-05-09-834_ad36f5ffb2c988b7.webp","sourceBytes":1032,"destBytes":770,"targetWebpQuality":75,"feedId":1531,"totalSpendMs":1448,"convertSpendMs":4,"createdTime":"2021-05-19 23:05:08","host":"europe68*","referer":"http://weixin.sogou.com/weixin?type=2&query=%E7%9F%A5%E8%AF%86%E5%88%86%E5%AD%90+NK%E5%85%8D%E7%96%AB%E7%BB%86%E8%83%9E%E7%96%97%E6%B3%95%EF%BC%9A%E4%B8%BA%E4%BD%95%E6%B2%A6%E4%B8%BA%E7%99%8C%E7%97%87%E6%82%A3%E8%80%85%E7%9A%84%20%E2%80%9C%E8%B6%85%E7%BA%A7%E6%9D%80%E6%89%8B%E2%80%9D%EF%BC%9F","linkMd5ListStr":"961fa44a0a3d9f053a24ad2e12e55620","githubUser":"myreaderx8","githubHttpCode":201,"extra22GetBytesInfo":"1、没有Referer字段","extra23historyStatusCode":[200],"sourceSize":"1 KB","destSize":"770 B","compressRate":"74.6%"},{"code":1,"isDone":false,"source":"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_jpg/LHibUTtMHPROiaSPyQU4nvX1SticyiaWicGm8CtriaDBpibJtP1OEEognohfVzia6wfheLzibjEkg8Q13VF1jsVkItyKXvA/640?wx_fmt=jpeg","sourceStatusCode":200,"destWidth":1080,"destHeight":273,"fixedGithubDest":"https://cdn.jsdelivr.net/gh/myreaderx27/cdn30@2020_5/2021/05/19/15-05-12-602_d15fb6d73d28a7d0.webp","sourceBytes":39187,"destBytes":27512,"targetWebpQuality":75,"feedId":1531,"totalSpendMs":6161,"convertSpendMs":17,"createdTime":"2021-05-19 23:05:06","host":"europe-60*","referer":"http://weixin.sogou.com/weixin?type=2&query=%E7%9F%A5%E8%AF%86%E5%88%86%E5%AD%90+NK%E5%85%8D%E7%96%AB%E7%BB%86%E8%83%9E%E7%96%97%E6%B3%95%EF%BC%9A%E4%B8%BA%E4%BD%95%E6%B2%A6%E4%B8%BA%E7%99%8C%E7%97%87%E6%82%A3%E8%80%85%E7%9A%84%20%E2%80%9C%E8%B6%85%E7%BA%A7%E6%9D%80%E6%89%8B%E2%80%9D%EF%BC%9F","linkMd5ListStr":"961fa44a0a3d9f053a24ad2e12e55620","githubUser":"myreaderx27","githubHttpCode":201,"extra22GetBytesInfo":"1、没有Referer字段","extra23historyStatusCode":[200],"sourceSize":"38.3 KB","destSize":"26.9 KB","compressRate":"70.2%"},{"code":1,"isDone":false,"source":"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_jpg/cyUibDfJJTsLu3ibSvvVmNBabkAnLK5ickhIiac5rIKPRyD5xv4Ee2I8fwVz2cm6azsocJLWcncDuj4xZicdXh6cQMA/640?wx_fmt=jpeg","sourceStatusCode":200,"destWidth":1080,"destHeight":717,"fixedGithubDest":"https://cdn.jsdelivr.net/gh/myreaderx25/cdn86@2020_2/2021/05/19/15-05-13-528_abe5105c38d24c6b.webp","sourceBytes":78062,"destBytes":52892,"targetWebpQuality":75,"feedId":1531,"totalSpendMs":7304,"convertSpendMs":22,"createdTime":"2021-05-19 23:05:06","host":"europe64*","referer":"http://weixin.sogou.com/weixin?type=2&query=%E7%9F%A5%E8%AF%86%E5%88%86%E5%AD%90+NK%E5%85%8D%E7%96%AB%E7%BB%86%E8%83%9E%E7%96%97%E6%B3%95%EF%BC%9A%E4%B8%BA%E4%BD%95%E6%B2%A6%E4%B8%BA%E7%99%8C%E7%97%87%E6%82%A3%E8%80%85%E7%9A%84%20%E2%80%9C%E8%B6%85%E7%BA%A7%E6%9D%80%E6%89%8B%E2%80%9D%EF%BC%9F","linkMd5ListStr":"961fa44a0a3d9f053a24ad2e12e55620","githubUser":"myreaderx25","githubHttpCode":201,"extra22GetBytesInfo":"1、没有Referer字段","extra23historyStatusCode":[200],"sourceSize":"76.2 KB","destSize":"51.7 KB","compressRate":"67.8%"},{"code":1,"isDone":false,"source":"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_png/LHibUTtMHPRM5Ud8d7rOrOJZmevzXI7jkWPQBKNS1T4U2CFbBsLHLZqKukUV52RiaDRiaVKuLnOshZeeEDWuDse3w/640?wx_fmt=png","sourceStatusCode":200,"destWidth":92,"destHeight":90,"fixedGithubDest":"https://cdn.jsdelivr.net/gh/myreaderx6/cdn31@2020_2/2021/05/19/15-05-14-111_8ae0aba223f05c44.webp","sourceBytes":4625,"destBytes":2870,"targetWebpQuality":75,"feedId":1531,"totalSpendMs":5739,"convertSpendMs":4,"createdTime":"2021-05-19 23:05:08","host":"europe61*","referer":"http://weixin.sogou.com/weixin?type=2&query=%E7%9F%A5%E8%AF%86%E5%88%86%E5%AD%90+NK%E5%85%8D%E7%96%AB%E7%BB%86%E8%83%9E%E7%96%97%E6%B3%95%EF%BC%9A%E4%B8%BA%E4%BD%95%E6%B2%A6%E4%B8%BA%E7%99%8C%E7%97%87%E6%82%A3%E8%80%85%E7%9A%84%20%E2%80%9C%E8%B6%85%E7%BA%A7%E6%9D%80%E6%89%8B%E2%80%9D%EF%BC%9F","linkMd5ListStr":"961fa44a0a3d9f053a24ad2e12e55620","githubUser":"myreaderx6","githubHttpCode":201,"extra22GetBytesInfo":"1、没有Referer字段","extra23historyStatusCode":[200],"sourceSize":"4.5 KB","destSize":"2.8 KB","compressRate":"62.1%"},{"code":1,"isDone":false,"source":"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_jpg/LHibUTtMHPRNtvz5A1gm8NxTXLPQMoXf0K20dY3OoG2icZfeM8lDarp6R6MFTcIsn0Z5B3AGvcMYQTEQYDqic7bHg/640?wx_fmt=jpeg","sourceStatusCode":200,"destWidth":1080,"destHeight":273,"fixedGithubDest":"https://cdn.jsdelivr.net/gh/myreaderx22/cdn19@2020_3/2021/05/19/15-05-17-763_c807840c2bc24160.webp","sourceBytes":37102,"destBytes":27030,"targetWebpQuality":75,"feedId":1531,"totalSpendMs":11063,"convertSpendMs":11,"createdTime":"2021-05-19 23:05:06","host":"us-010*","referer":"http://weixin.sogou.com/weixin?type=2&query=%E7%9F%A5%E8%AF%86%E5%88%86%E5%AD%90+NK%E5%85%8D%E7%96%AB%E7%BB%86%E8%83%9E%E7%96%97%E6%B3%95%EF%BC%9A%E4%B8%BA%E4%BD%95%E6%B2%A6%E4%B8%BA%E7%99%8C%E7%97%87%E6%82%A3%E8%80%85%E7%9A%84%20%E2%80%9C%E8%B6%85%E7%BA%A7%E6%9D%80%E6%89%8B%E2%80%9D%EF%BC%9F","linkMd5ListStr":"961fa44a0a3d9f053a24ad2e12e55620","githubUser":"myreaderx22","githubHttpCode":201,"extra22GetBytesInfo":"1、没有Referer字段","extra23historyStatusCode":[200],"sourceSize":"36.2 KB","destSize":"26.4 KB","compressRate":"72.9%"},{"code":1,"isDone":false,"source":"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_png/cyUibDfJJTsLu3ibSvvVmNBabkAnLK5ickh9aoicwSLsqicAtt4FAQxtTrVyoibYcfRhHnZPRTZZLzUXibrfmjHU325xg/640?wx_fmt=png","sourceStatusCode":200,"destWidth":641,"destHeight":352,"fixedGithubDest":"https://cdn.jsdelivr.net/gh/myreaderx1/cdn97@2020_2/2021/05/19/15-05-31-307_57b1a39ae6f7d840.webp","sourceBytes":118126,"destBytes":26682,"targetWebpQuality":75,"feedId":1531,"totalSpendMs":24655,"convertSpendMs":15,"createdTime":"2021-05-19 23:05:06","host":"us-005*","referer":"http://weixin.sogou.com/weixin?type=2&query=%E7%9F%A5%E8%AF%86%E5%88%86%E5%AD%90+NK%E5%85%8D%E7%96%AB%E7%BB%86%E8%83%9E%E7%96%97%E6%B3%95%EF%BC%9A%E4%B8%BA%E4%BD%95%E6%B2%A6%E4%B8%BA%E7%99%8C%E7%97%87%E6%82%A3%E8%80%85%E7%9A%84%20%E2%80%9C%E8%B6%85%E7%BA%A7%E6%9D%80%E6%89%8B%E2%80%9D%EF%BC%9F","linkMd5ListStr":"961fa44a0a3d9f053a24ad2e12e55620","githubUser":"myreaderx1","githubHttpCode":201,"extra22GetBytesInfo":"1、没有Referer字段","extra23historyStatusCode":[200],"sourceSize":"115.4 KB","destSize":"26.1 KB","compressRate":"22.6%"}],"successGithubMap":{"myreaderx8":1,"myreaderx25":1,"myreaderx27":1,"myreaderx6":1,"myreaderx10":1,"myreaderx21":1,"myreaderx22":1,"myreaderx12":1,"myreaderx1":1,"myreaderx30":1,"myreaderx5oss":1},"failGithubMap":{"myreaderx23":1,"myreaderx31":1}}